Exosome-Based Therapeutics: A Natural Solution to Overcoming the Blood–Brain Barrier in Neurodegenerative Diseases

Abstract

Neurodegenerative diseases present significant therapeutic challenges, primarily due to the restrictive nature of the blood–brain barrier (BBB), which limits drug delivery to the brain. While the BBB is crucial for protecting the brain from harmful substances, it also hinders the effectiveness of treatments for neurodegenerative diseases. Consequently, there is an urgent need for innovative drug delivery systems capable of bypassing the BBB to improve therapeutic outcomes. Exosomes, as endogenous nanoscale carriers, offer substantial promise for brain-targeted drug delivery. Their unique characteristics, including the ability to cross biological barriers, high biocompatibility, intrinsic targeting capacity, natural intracellular transport mechanisms, and robust stability, render them highly promising candidates for drug delivery in the treatment of neurodegenerative disorders. This review delves into various engineering strategies for exosome-mediated targeted drug delivery and provides an in-depth analysis of the structural and functional properties of the BBB under normal and pathological conditions. We emphasize the potential of exosomes as drug delivery vehicles for the central nervous system, particularly in addressing neurodegenerative disorders. Furthermore, we address the key obstacles to the clinical application of exosome-based therapies and propose future research directions aimed at optimizing these methods to develop more effective treatment strategies.

Keywords

blood–brain barrier / drug delivery systems / exosomes / neurodegeneration therapy / neurodegenerative diseases

References

[1] V. Singh, A. Garg, R. Sharma, and H. K. Dewangan, “Recent Advances of Nanotechnology in Brain Targeting,” Current Nanoscience 19, no. 3 (2023): 350-361.

[2] N. Tournier and O. Langer, “Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria,” Journal of Nuclear Medicine 66, no. 5 (2025): 676-680.

[3] I. Gaurav, A. Thakur, A. Iyaswamy, et al., “Factors Affecting Extracellular Vesicles Based Drug Delivery Systems,” Molecules (Basel, Switzerland) 26, no. 6 (2021): 1544.

[4] P. Vader, E. A. Mol, G. Pasterkamp, and R. M. Schiffelers, “Extracellular Vesicles for Drug Delivery,” Advanced Drug Delivery Reviews 106, no. part A (2016): 148-156.

[5] I. K. Herrmann, M. J. A. Wood, and G. Fuhrmann, “Extracellular Vesicles as a Next-Generation Drug Delivery Platform,” Nature Nanotechnology 16, no. 7 (2021): 748-759.

[6] R. Tenchov, R. Bird, A. E. Curtze, and Q. Zhou, “Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement,” ACS Nano 15, no. 11 (2021): 16982-17015.

[7] B. Begines, T. Ortiz, M. Perez-Aranda, et al., “Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects,” Nanomaterials 10, no. 7 (2020): 1043.

[8] O. M. Elsharkasy, J. Z. Nordin, D. W. Hagey, et al., “Extracellular Vesicles as Drug Delivery Systems: Why and How?,” Advanced Drug Delivery Reviews 159, no. 1 (2020): 332-343.

[9] Q. Zhang, H. Chen, L. Wu, and H. Chen, “An Anionic and Proline-Rich Peptide Prolonged Blood Circulation of Liposomes and Evaded Accelerated Blood Clearance After Repeated Administration,” Journal of Controlled Release 378, no. 1 (2025): 534-542.

[10] S. Ding, A. I. Khan, X. Cai, et al., “Overcoming Blood-Brain Barrier Transport: Advances in Nanoparticle-Based Drug Delivery Strategies,” Materials Today 37, no. 1 (2020): 112-125.

[11] Y. Li, U. Ettah, S. Jacques, et al., “Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated With PEGylated Liposomal Doxorubicin,” Molecular Pharmaceutics 21, no. 6 (2024): 3053-3060.

[12] H. Guo and P. Mi, “Polymer-Drug and Polymer-Protein Conjugated Nanocarriers: Design, Drug Delivery, Imaging, Therapy, and Clinical Applications,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 16, no. 4 (2024): 1988.

[13] O. M. Elsharkasy, J. Z. Nordin, D. W. Hagey, et al., “Extracellular Vesicles as Drug Delivery Systems: Why and How?,” Advanced Drug Delivery Reviews 159, no. 3 (2020): 332-343.

[14] W. Zhang, A. Refaat, H. Li, et al., “Optimizing Angiopep-2 Density on Polymeric Nanoparticles for Enhanced Blood-Brain Barrier Penetration and Glioblastoma Targeting: Insights From in Vitro and in Vivo Experiments,” Advanced Functional Materials 1, no. 1 (2025): 2425165.

[15] J. Di, F. Xie, and Y. Xu, “When Liposomes Met Antibodies: Drug Delivery and Beyond,” Advanced Drug Delivery Reviews 154, no. 1 (2020): 151-162.

[16] P. Wolf, “The Nature and Significance of Platelet Products in Human Plasma,” British Journal of Haematology 13, no. 3 (1967): 269-288.

[17] S. Gurunathan, M.-H. Kang, M. Jeyaraj, M. Qasim, and J.-H. Kim, “Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes,” Cells 8, no. 4 (2019): 307.

[18] C. K. Das, B. C. Jena, I. Banerjee, et al., “Exosome as a Novel Shuttle for Delivery of Therapeutics Across Biological Barriers,” Molecular Pharmaceutics 16, no. 1 (2019): 24-40.

[19] S. G. Antimisiaris, S. Mourtas, and A. Marazioti, “Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery,” Pharmaceutics 10, no. 4 (2018): 218.

[20] J. J. Lai, Z. L. Chau, S.-Y. Chen, et al., “Exosome Processing and Characterization Approaches for Research and Technology Development,” Advancement of Science 9, no. 15 (2022): 210322.

[21] H. Peng, W. Ji, and R. Zhao, “Exosome: A Significant Nano-Scale Drug Delivery Carrier,” Journal of Materials Chemistry B 8, no. 34 (2020): 7591-7608.

[22] H. Song, B. Liu, B. Dong, et al., “Exosome-Based Delivery of Natural Products in Cancer Therapy,” Frontiers in Cell and Developmental Biology 9, no. 5 (2021): 650426.

[23] W. Ahmed, A. Mushtaq, S. Ali, et al., “Engineering Approaches for Exosome Cargo Loading and Targeted Delivery: Biological Versus Chemical Perspectives,” ACS Biomaterials Science & Engineering 10, no. 10 (2024): 5960-5976.

[24] L. Cabeza, G. Perazzoli, M. Pena, et al., “Cancer Therapy Based on Extracellular Vesicles as Drug Delivery Vehicles,” Journal of Controlled Release 327, no. 4 (2020): 296-315.

[25] T. Chen, Y. Dai, C. Hu, et al., “Cellular and Molecular Mechanisms of the Blood-Brain Barrier Dysfunction in Neurodegenerative Diseases,” Fluids Barriers CNS 21, no. 1 (2024): 21-88.

[26] J. Nowell, E. Blunt, and P. Edison, “Incretin and Insulin Signaling as Novel Therapeutic Targets for Alzheimer's and Parkinson's Disease,” Molecular Psychiatry 28, no. 1 (2023): 217-229.

[27] H. Tong, T. Yang, S. Xu, et al., “Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies,” International Journal of Molecular Sciences 25, no. 7 (2024): 38-45.

[28] L. Nguyen, “Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis,” Cells 13, no. 11 (2024): 888.

[29] W. Barrie, Y. Yang, and E. K. Irving-Pease, “Elevated Genetic Risk for Multiple Sclerosis Emerged in Steppe Pastoralist Populations,” Nature 625, no. 7994 (2024): 321-328.

[30] F. Mehryab, S. Rabbani, S. Shahhosseini, et al., “Exosomes as a Next-Generation Drug Delivery System: An Update on Drug Loading Approaches, Characterization, and Clinical Application Challenges,” Acta Biomaterialia 113, no. 5 (2020): 42-62.

[31] N. Dilsiz, “Exosomes as New Generation Vehicles for Drug Delivery Systems,” Journal of Drug Delivery Science and Technology 95, no. 2 (2024): 150-562.

[32] L. Filipovic, M. Kojadinovic, and M. Popovic, “Exosomes and Exosome-Mimetics as Targeted Drug Carriers: Where We Stand and What the Future Holds?,” Journal of Drug Delivery Science and Technology 68, no. 12 (2022): 103057.

[33] T. Croese and R. Furlan, “Extracellular Vesicles in Neurodegenerative Diseases,” Molecular Aspects of Medicine 60, no. 8 (2018): 52-61.

[34] P. Gao, X. Li, X. Du, S. Liu, and Y. Xu, “Diagnostic and Therapeutic Potential of Exosomes in Neurodegenerative Diseases,” Frontiers in Aging Neuroscience 13, no. 5 (2021): 790-863.

[35] H. Chen, N. Li, Y. Cai, et al., “Exosomes in Neurodegenerative Diseases: Therapeutic Potential and Modification Methods,” Neural Regeneration Research 21, no. 2 (2026): 478-490.

[36] S. Salarpour, M. Barani, A. Pardakhty, M. Khatami, and N. P. S. Chauhan, “The Application of Exosomes and Exosome-Nanoparticle in Treating Brain Disorders,” Journal of Molecular Liquids 350, no. 1 (2022): 118-549.

[37] F. U. Rehman, Y. Liu, M. Zheng, and B. Shi, “Exosomes Based Strategies for Brain Drug Delivery,” Biomaterials 293, no. 9 (2023): 121949.

[38] S. Bashyal, C. Thapa, and S. Lee, “Recent Progresses in Exosome-Based Systems for Targeted Drug Delivery to the Brain,” Journal of Controlled Release 348, no. 6 (2022): 723-744.

[39] A. Kadbhane, M. Patel, S. Srivastava, et al., “Perspective Insights and Application of Exosomes as a Novel Tool Against Neurodegenerative Disorders: An Expository Appraisal,” Journal of Drug Delivery Science and Technology 63, no. 6 (2021): 102526.

[40] E. Chargaff and R. West, “The Biological Significance of the Thromboplastic Protein of Blood,” Journal of Biological Chemistry 166, no. 1 (1946): 189-197.

[41] R. M. Johnstone, M. Adam, J. R. Hammond, L. Orr, and C. Turbide, “Vesicle Formation During Reticulocyte Maturation. Association of Plasma Membrane Activities With Released Vesicles (exosomes),” Journal of Biological Chemistry 262, no. 19 (1987): 9412-9420.

[42] A. Javdani-Mallak and I. Salahshoori, “Environmental Pollutants and Exosomes: A New Paradigm in Environmental Health and Disease,” Science of the Total Environment 925, no. 1 (2024): 171774.

[43] M. Guerra-Andres, A. F. Fernandez, and T. Fontanil, “Exosomes, Autophagy, and Cancer: A Complex Triad,” International Journal of Cancer 157, no. 3 (2025): 405-415.

[44] S. V. Krylova and D. Feng, “The Machinery of Exosomes: Biogenesis, Release, and Uptake,” International Journal of Molecular Sciences 24, no. 2 (2023): 1337.

[45] Y. J. Lee, K. J. Shin, and Y. C. Chae, “Regulation of Cargo Selection in Exosome Biogenesis and Its Biomedical Applications in Cancer,” Experimental & Molecular Medicine 56, no. 4 (2024): 877-889.

[46] S. Araujo-Abad, J. M. Berna, E. Lloret-Lopez, et al., “Exosomes: From Basic Research to Clinical Diagnostic and Therapeutic Applications in Cancer,” Cellular Oncology 48, no. 2 (2025): 269-293.

[47] R. Kalluri and V. S. LeBleu, “The Biology, Function, and Biomedical Applications of Exosomes,” Science 367, no. 6478 (2020): 640-780.

[48] C. C. Huber and H. Wang, “Pathogenic and Therapeutic Role of Exosomes in Neurodegenerative Disorders,” Neural Regeneration Research 19, no. 1 (2024): 75-79.

[49] S. R. Goodman, “The Exosome Collection,” Cellular & Molecular Biology Letters 30, no. 1 (2025): 33.

[50] Q.-F. Han, W.-J. Li, K.-S. Hu, et al., “Exosome Biogenesis: Machinery, Regulation, and Therapeutic Implications in Cancer,” Molecular Cancer 21, no. 1 (2022): 207.

[51] W. Liao, Y. Du, C. Zhang, et al., “Exosomes: The Next Generation of Endogenous Nanomaterials for Advanced Drug Delivery and Therapy,” Acta Biomaterialia 86, no. 7 (2019): 1-14.

[52] C. Liu, D. Liu, S. Wang, et al., “Identification of the SNARE Complex That Mediates the Fusion of Multivesicular Bodies With the Plasma Membrane in Exosome Secretion,” Journal of Extracellular Vesicles 12, no. 9 (2023): 12356.

[53] V. Sholokhov, E. V. Makoveeva, S. Fedotov, and D. V. Alexandrov, “Stochastic Nonlinear Model for Nanoparticles and Viruses Escape From Endosomes,” The European Physical Journal Special Topics 233, no. 23-24 (2024): 3341-3347.

[54] N. P. Hessvik and A. Llorente, “Current Knowledge on Exosome Biogenesis and Release,” Cellular and Molecular Life Sciences 75, no. 2 (2018): 193-208.

[55] S. Mehdizadeh, M. Mamaghani, S. Hassanikia, Y. Pilehvar, and Y. N. Ertas, “Exosome-Powered Neuropharmaceutics: Unlocking the Blood-Brain Barrier for Next-Gen Therapies,” Journal of Nanbiotechnology 23, no. 1 (2025): 329-334.

[56] Exosomes. Nature Biotechnology 2020; 38(10): 1150-1150.

[57] A. Wells, C. C. Mendes, F. Castellanos, et al., “A Rab6 to Rab11 Transition Is Required for Dense-Core Granule and Exosome Biogenesis in Drosophila Secondary Cells,” PLOS Genetics 19, no. 10 (2023): e1010979-e1010979.

[58] D. K. Jeppesen, J. L. Franklin, J. N. Higginbotham, Q. Zhang, and R. J. Coffey, “Reassessment of Exosome Composition,” Cancer Research 79, no. 13 (2019): 428-445.

[59] Y. Fan, C. Pionneau, F. Cocozza, et al., “Differential Proteomics Argues Against a General Role for CD9, CD81 or CD63 in the Sorting of Proteins Into Extracellular Vesicles,” Journal of Extracellular Vesicles 12, no. 8 (2023): 12352.

[60] S. E. Sedykh, L. V. Purvinsh, E. E. Burkova, et al., “Analysis of Proteins and Peptides of Highly Purified CD9 + and CD63 + Horse Milk Exosomes Isolated by Affinity Chromatography,” International Journal of Molecular Sciences 23, no. 24 (2022): 16106.

[61] J. Shen, Q. Zhao, X. Wang, et al., “A Plant Bro1 Domain Protein BRAF Regulates Multivesicular Body Biogenesis and Membrane Protein Homeostasis (vol 9,3784,2018),” Nature Communications 16, no. 1 (2025): 3784.

[62] I. Giusti, G. Poppa, and S. D'Ascenzo, “Cancer Three-Dimensional Spheroids Mimic in Vivo Tumor Features, Displaying “Inner” Extracellular Vesicles and Vasculogenic Mimicry,” International Journal of Molecular Sciences 23, no. 19 (2022): 11782.

[63] M. Regimbeau, J. Abrey, V. Vautrot, et al., “Heat Shock Proteins and Exosomes in Cancer Theranostics,” Seminars in Cancer Biology 86, no. 1 (2022): 46-57.

[64] M. Nishio, Y. Teranishi, K. Morioka, A. Yanagida, and A. Shoji, “Real-Time Assay for Exosome Membrane Fusion With an Artificial Lipid Membrane Based on Enhancement of Gramicidin A Channel Conductance,” Biosensors & Bioelectronics 150, no. 1 (2020): 111918.

[65] Y. Arima, W. Liu, Y. Takahashi, M. Nishikawa, and Y. Takakura, “Effects of Localization of Antigen Proteins in Antigen-Loaded Exosomes on Efficiency of Antigen Presentation,” Molecular Pharmaceutics 16, no. 6 (2019): 2309-2314.

[66] M. F. S. Lindenbergh, R. Wubbolts, E. G. F. Borg, et al., “Dendritic Cells Release Exosomes Together With Phagocytosed Pathogen; Potential Implications for the Role of Exosomes in Antigen Presentation,” Journal of Extracellular Vesicles 9, no. 1 (2020): 8606.

[67] A. M. Erasha, H. El-Gendy, A. S. Aly, M. Fernandez-Ortiz, and R. K. A. Sayed, “The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes,” International Journal of Molecular Sciences 26, no. 6 (2025): 2716.

[68] A. B. Hashkavayi, A. Alizadeh, and H. Chun, “Review of Advances in Glycan Analysis on Exosomes, Cancer Cells, and Circulating Cancer-Derived Glycoproteins With an Emphasis on Electrochemistry,” Analytica Chimica Acta 1336, no. 1 (2025): 343277.

[69] H. Basma, A. N. Johanson, K. Dhar, et al., “TGF-β Induces a Heart Failure Phenotype via Fibroblasts Exosome Signaling,” Heliyon 5, no. 10 (2019): e02633.

[70] Y. Huang, M. Kanada, J. Ye, et al., “Exosome-Mediated Remodeling of the Tumor Microenvironment: From Local to Distant Intercellular Communication,” Cancer Letters 543, no. 1 (2022): 215796.

[71] M. Lu, M. Capello, S. C. Tripathi, et al., “The Role of Exosome-Mediated Cell-Cell Communication in Inducing Phenotypic Changes,” Cancer Research 76, no. 3 (2016): 1479.

[72] E. Yang, X. Wang, Z. Gong, et al., “Exosome-Mediated Metabolic Reprogramming: The Emerging Role in Tumor Microenvironment Remodeling and Its Influence on Cancer Progression,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 252.

[73] Q. Wu, Z. Xie, X. Cao, et al., “Chaihu-Shugan-San Alleviates Post-Stroke Depression in Mice: Mechanistic Insights Into Exosome-Mediated Neuroprotection,” Journal of Ethnopharmacology 347, no. 12 (2025): 119700.

[74] C. Ma, Y. Li, B. Liu, et al., “Exosomes Derived From Adipose Mesenchymal Stem Cells Promote Corneal Injury Repair and Inhibit the Formation of Scars by Anti-Apoptosis,” Colloids and Surfaces. B, Biointerfaces 247, no. 1 (2025): 114454.

[75] N. Yuan, L. Xiao, J. Chen, et al., “CREG1 Promotes Bovine Placental Trophoblast Cells Exosome Release by Targeting IGF2R and Participates in Regulating Organoid Differentiation via Exosomes Transport,” International Journal of Biological Macromolecules 274, no. 1 (2024): 133298.

[76] R. Begum, D. Mutyala, S. Thota, N. Bidarimath, and S. Batra, “Compartmentalization of Proteasomes in Lipid Rafts and Exosomes: Unveiling Molecular Interactions in Vaping-Related Cellular Processes,” Archives of Toxicology 99, no. 6 (2025): 2493-2505.

[77] M. Mathieu, L. Martin-Jaular, G. Lavieu, and C. Thery, “Specificities of Secretion and Uptake of Exosomes and Other Extracellular Vesicles for Cell-to-Cell Communication,” Nature Cell Biology 21, no. 1 (2019): 9-17.

[78] A. Amiri, R. Bagherifar, E. A. Dezfouli, et al., “Exosomes as Bio-Inspired Nanocarriers for RNA Delivery: Preparation and Applications,” Journal of translational medicine 20, no. 1 (2022): 125.

[79] J. Donoso-Quezada, S. Ayala-Mar, and J. Gonzalez-Valdez, “The Role of Lipids in Exosome Biology and Intercellular Communication: Function, Analytics and Applications,” Traffic (Copenhagen, Denmark) 22, no. 7 (2021): 204-220.

[80] Y. Men, J. Yelick, and S. Jin, “Exosome Reporter Mice Reveal the Involvement of Exosomes in Mediating Neuron to Astroglia Communication in the CNS,” Nature Communications 10, no. 1 (2019): 4136.

[81] P. Yuan, L. Ding, H. Chen, et al., “Neural Stem Cell-Derived Exosomes Regulate Neural Stem Cell Differentiation Through miR-9-Hes1 Axis,” Frontiers in Cell and Developmental Biology 09, no. 1 (2021): 33-89.

[82] G. Singh, A. Mehra, S. Arora, et al., “Exosome-Mediated Delivery and Regulation in Neurological Disease Progression,” International Journal of Biological Macromolecules 264, no. 4 (2024): 130728.

[83] Q. D. Trinh, H. N. Mai, and D. T. Pham, “Application of Mesenchymal Stem Cells for Neurodegenerative Diseases Therapy Discovery,” Regenerative Therapy 26, no. 1 (2024): 981-989.

[84] J. Li, H. Gao, Y. Xiong, et al., “Enhancing Cutaneous Wound Healing Based on Human Induced Neural Stem Cell-Derived Exosomes,” International Journal of Nanomedicine 17, no. 4 (2022): 5991-6006.

[85] K. Sharma, Y. Zhang, K. R. Paudel, et al., “The Emerging Role of Pericyte-Derived Extracellular Vesicles in Vascular and Neurological Health,” Cells 11, no. 19 (2022): 3108.

[86] L. Jiang, H. Dong, H. Cao, et al., “Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease,” Medical Science Monitor 25, no. 2 (2019): 3329-3335.

[87] Y. Zhang, M. S. Kim, B. Jia, et al., “Hypothalamic Stem Cells Control Ageing Speed Partly Through Exosomal miRNAs,” Nature 548, no. 7665 (2017): 52-57.

[88] R. Isaac, F. C. G. Reis, W. Ying, and J. M. Olefsky, “Exosomes as Mediators of Intercellular Crosstalk in Metabolism,” Cell Metabolism 33, no. 9 (2021): 1744-1762.

[89] I. Wortzel, S. Dror, C. M. Kenific, and D. Lyden, “Exosome-Mediated Metastasis: Communication From a Distance,” Developmental Cell 49, no. 3 (2019): 347-360.

[90] Y. Li, J. Zhou, Y.-H. Song, and X.-Y. Yu, “Dominant and Recessive Imprinting of Exosomes From Parent Cells,” Nature Reviews Cardiology 14, no. 8 (2017): 492-492.

[91] K. Hirohata, S. Kino, T. Yamane, et al., “Use of Cesium Chloride Density Gradient Ultracentrifugation for the Purification and Characterization of Recombinant Adeno-Associated Virus,” European Biophysics Journal 6, no. 1 (2025): 645.

[92] N. Mukerjee, A. Bhattacharya, S. Maitra, et al., “Exosome Isolation and Characterization for Advanced Diagnostic and Therapeutic Applications,” Materials Today Bio 31, no. 1 (2025): 101603.

[93] D. A. A. Raj, I. Fiume, G. Capasso, and G. Pocsfalvi, “A Multiplex Quantitative Proteomics Strategy for Protein Biomarker Studies in Urinary Exosomes,” Kidney International 81, no. 12 (2012): 1263-1272.

[94] K. Li, D. K. Wong, K. Y. Hong, and R. L. Raffai, “Cushioned-Density Gradient Ultracentrifugation (C-DGUC): A Refined and High Performance Method for the Isolation, Characterization, and Use of Exosomes,” Methods in Molecular Biology 1740, no. 1 (2018): 69-83.

[95] K. A. Konadu, M. B. Huang, W. Roth, et al., “Isolation of Exosomes From the Plasma of HIV-1 Positive Individuals,” Journal of Visualized Experiments: JoVE 112, no. 107 (2016): e54382.

[96] S. M. Langevin, D. Kuhnell, M. A. Orr-Asman, et al., “Balancing Yield, Purity and Practicality: A Modified Differential Ultracentrifugation Protocol for Efficient Isolation of Small Extracellular Vesicles From Human Serum,” RNA Biology 16, no. 1 (2019): 5-12.

[97] P. Li, M. Kaslan, S. H. Lee, J. Yao, and Z. Gao, “Progress in Exosome Isolation Techniques,” Theranostics 7, no. 3 (2017): 789-804.

[98] J. Yang, X. Gao, X. Xing, et al., “An Isolation System to Collect High Quality and Purity Extracellular Vesicles From Serum,” International Journal of Nanomedicine 16, no. 1 (2021): 6681-6692.

[99] Y. Weng, Z. Sui, Y. Shan, et al., “Effective Isolation of Exosomes With Polyethylene Glycol From Cell Culture Supernatant for in-Depth Proteome Profiling,” Analyst 141, no. 15 (2016): 4640-4646.

[100] S. Guan, H. Yu, G. Yan, et al., “Characterization of Urinary Exosomes Purified With Size Exclusion Chromatography and Ultracentrifugation,” Journal of Proteome Research 19, no. 6 (2020): 2217-2225.

[101] X. Liu, Z. Zong, X. Liu, et al., “Stimuli-Mediated Specific Isolation of Exosomes From Blood Plasma for High-Throughput Profiling of Cancer Biomarkers,” Small Methods 6, no. 2 (2022): 2101170.

[102] M. Yamauchi, K. Shimizu, M. Rahman, et al., “Efficient Method for Isolation of Exosomes From Raw Bovine Milk,” Drug Development and Industrial Pharmacy 45, no. 3 (2019): 359-364.

[103] E. Gonzalez-Cubero, M. L. Gonzalez-Fernandez, L. Gutierrez-Velasco, E. Navarro-Ramirez, and V. Villar-Suarez, “Isolation and Characterization of Exosomes From Adipose Tissue-Derived Mesenchymal Stem Cells,” Journal of Anatomy 238, no. 5 (2021): 1203-1217.

[104] S. L. Moura, M. Marti, and M. I. Pividori, “Matrix Effect in the Isolation of Breast Cancer-Derived Nanovesicles by Immunomagnetic Separation and Electrochemical Immunosensing-A Comparative Study,” Sensors (Basel) 20, no. 4 (2020): 965.

[105] A.-K. Ludwig, K. De Miroschedji, T. R. Doeppner, et al., “Precipitation With Polyethylene Glycol Followed by Washing and Pelleting by Ultracentrifugation Enriches Extracellular Vesicles From Tissue Culture Supernatants in Small and Large Scales,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1528109.

[106] A. Lal, J. F. W. Pike, E. L. Polley, et al., “Comparison of RNA Content From Hydrophobic Interaction Chromatography-Isolated Seminal Plasma Exosomes From Intrauterine Insemination (IUI) Pregnancies,” Andrologia 54, no. 2 (2022): e14383.

[107] J. Lee, H. Kim, Y. Heo, et al., “Enhanced Paper-Based ELISA for Simultaneous EVs/Exosome Isolation and Detection Using Streptavidin Agarose-Based Immobilization,” Analyst 145, no. 1 (2020): 157-164.

[108] F. Barati, A. M. Farsani, and M. Mahmoudifard, “A Promising Approach Toward Efficient Isolation of the Exosomes by Core-Shell PCL-Gelatin Electrospun Nanofibers,” Bioprocess and Biosystems Engineering 43, no. 11 (2020): 1961-1971.

[109] M. A. Livshits, E. Khomyakova, E. G. Evtushenko, et al., “Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a Commonly Used Protocol (vol 5, 17319, 2015),” Scientific Reports 6, no. 6 (2016): 21447.

[110] A. Yokoi, K. Yoshida, H. Koga, et al., “Spatial Exosome Analysis Using Cellulose Nanofiber Sheets Reveals the Location Heterogeneity of Extracellular Vesicles,” Nature Communications 14, no. 1 (2023): 6915.

[111] F. Kong, M. Upadya, A. S. W. Wong, R. Dalan, and M. Dao, “Isolating Small Extracellular Vesicles From Small Volumes of Blood Plasma Using Size Exclusion Chromatography and Density Gradient Ultracentrifugation: A Comparative Study,” BioRxiv 10, no. 1 (2025): 564707.

[112] R. Bharti, M. Kumar, V. Devi, et al., “Efficient Isolation and Characterization of Serum-Derived Exosomes: Evaluating Ultracentrifugation and Total Exosome Isolation Reagent Based Precipitation,” Ultrastructural Pathology 12, no. 1 (2025): 2507698.

[113] Q. Zhang, H. Wang, Q. Liu, et al., “Exosomes as Powerful Biomarkers in Cancer: Recent Advances in Isolation and Detection Techniques,” International Journal of Nanomedicine 19, no. 1 (2024): 1923-1949.

[114] E. Ciftci, N. Bozbeyoglu, I. Gursel, et al., “Comparative Analysis of Magnetically Activated Cell Sorting and Ultracentrifugation Methods for Exosome Isolation,” PLoS ONE 18, no. 2 (2023): e282238.

[115] A. Teixeira-Marques, S. Monteiro-Reis, D. Montezuma, et al., “Improved Recovery of Urinary Small Extracellular Vesicles by Differential Ultracentrifugation,” Scientific Reports 14, no. 1 (2024): 12267.

[116] K. Tiszbein, I. Koss-Mikolajczyk, and D. Martysiak-Zurowska, “Unlocking the Secrets of Human Milk: Isolation and Characterization of Extracellular Vesicles,” Advances in Nutrition 16, no. 6 (2025): 100430.

[117] T. K. Kurian, S. Banik, D. Gopal, S. Chakrabarti, and N. Mazumder, “Elucidating Methods for Isolation and Quantification of Exosomes: A Review,” Molecular Biotechnology 63, no. 4 (2021): 249-266.

[118] K. Sidhom, P. O. Obi, and A. Saleem, “A Review of Exosomal Isolation Methods: Is Size Exclusion Chromatography the Best Option?,” International Journal of Molecular Sciences 21, no. 18 (2020): 64-66.

[119] Y. Liu, Y. Huang, Q. Huang, et al., “A Novel Method for Isolation of Exosomes From Synovial Fluid,” Annals of the Rheumatic Diseases 80, no. 1 (2021): 1057-1057.

[120] W.-Z. Liu, Z.-J. Ma, and X.-W. Kang, “Current Status and Outlook of Advances in Exosome Isolation,” Analytical and Bioanalytical Chemistry 414, no. 24 (2022): 7123-7141.

[121] S. Gupta, S. Rawat, V. Arora, et al., “An Improvised One-Step Sucrose Cushion Ultracentrifugation Method for Exosome Isolation From Culture Supernatants of Mesenchymal Stem Cells,” Stem Cell Research & Therapy 9, no. 1 (2018), https://doi.org/10.1186/s13287-018-0923-0.

[122] F. A. Siebzehnrubl, K. A. Reber, Y. K. Urbach, et al., “Early Postnatal Behavioral, Cellular, and Molecular Changes in Models of Huntington Disease Are Reversible by HDAC Inhibition,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 37 (2018): E8765-E8774.

[123] E. V. Balaji, D. Ramesh, M. C. Shaju, et al., “Biological, Pathological, and Multifaceted Therapeutic Functions of Exosomes to Target Cancer,” Oncology Research 32, no. 1 (2024): 73-94.

[124] Y. Q. Koh, F. B. Almughlliq, K. Vaswani, H. N. Peiris, and M. D. Mitchell, “Exosome Enrichment by Ultracentrifugation and Size Exclusion Chromatography,” Frontiers in Bioscience (Landmark Ed) 23, no. 2 (2018): 865-874.

[125] T. S. Martins, J. Catita, I. M. Rosa, O. A. B. da Cruz e Silva, and A. G. Henriques, “Exosome Isolation From Distinct Biofluids Using Precipitation and Column-Based Approaches,” PLoS ONE 13, no. 6 (2018): e198820.

[126] A.-K. Ludwig, K. De Miroschedji, T. R. Doeppner, et al., “Precipitation With Polyethylene Glycol Followed by Washing and Pelleting by Ultracentrifugation Enriches Extracellular Vesicles From Tissue Culture Supernatants in Small and Large Scales,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1521029.

[127] S. M. Mousavi, S. M. A. Mahdian, M. S. Ebrahimi, et al., “Microfluidics for Detection of Exosomes and microRNAs in Cancer: State of the Art,” Molecular Therapy Nucleic Acids 28, no. 1 (2022): 758-791.

[128] X. Guo, F. Hu, S. Zhao, et al., “Immunomagnetic Separation Method Integrated With the Strep-Tag II System for Rapid Enrichment and Mild Release of Exosomes,” Analytical Chemistry 95, no. 7 (2023): 3569-3576.

[129] X. Xiang, F. Guan, F. Jiao, et al., “A New Urinary Exosome Enrichment Method by a Combination of Ultrafiltration and TiO₂ Nanoparticles,” Analytical Methods 13, no. 13 (2021): 1591-1600.

[130] J. Wang, P. Ma, D. H. Kim, B.-F. Liu, and U. Demirci, “Towards Microfluidic-Based Exosome Isolation and Detection for Tumor Therapy,” Nano Today 37, no. 1 (2021): 101066.

[131] M. Omrani, H. Beyrampour-Basmenj, R. Jahanban-Esfahlan, et al., “Global Trend in Exosome Isolation and Application: An Update Concept in Management of Diseases,” Molecular and Cellular Biochemistry 479, no. 3 (2024): 679-691.

[132] L. Filipovic, M. Spasojevic, R. Prodanovic, et al., “Affinity-Based Isolation of Extracellular Vesicles by Means of Single-Domain Antibodies Bound to Macroporous Methacrylate-Based Copolymer,” New Biotechnology 69, no. 1 (2022): 36-48.

[133] D. Yang, W. Zhang, H. Zhang, et al., “Progress, Opportunity, and Perspective on Exosome Isolation—efforts for Efficient Exosome-Based Theranostics,” Theranostics 10, no. 8 (2020): 3684-3707.

[134] Y. Pan, T. Ma, Q. Meng, et al., “Droplet Digital PCR Enabled by Microfluidic Impact Printing for Absolute Gene Quantification,” Talanta 211, no. 1 (2020): 120680.

[135] F. Schlenker, E. Kipf, N. Borst, et al., “Centrifugal Microfluidic Integration of 4-Plex ddPCR Demonstrated by the Quantification of Cancer-Associated Point Mutations,” Processes 9, no. 1 (2021): 97.

[136] S.-A. Hsieh, D. Shamsaei, D. R. Eitzmann, and J. L. Anderson, “Digital Droplet Loop-Mediated Isothermal Amplification Featuring a Molecular Beacon Assay, 3D Printed Droplet Generation, and Smartphone Imaging for Sequence-Specific DNA Detection,” Analytical Chemistry 94, no. 34 (2022): 11949-11956.

[137] C. L. Hisey, K. D. P. Dorayappan, D. E. Cohn, K. Selvendiran, and D. J. Hansford, “Microfluidic Affinity Separation Chip for Selective Capture and Release of Label-Free Ovarian Cancer Exosomes,” Lab on A Chip 18, no. 20 (2018): 3144-3153.

[138] M. Tayebi, Y. Zhou, P. Tripathi, R. Chandramohanadas, and Y. Ai, “Exosome Purification and Analysis Using a Facile Microfluidic Hydrodynamic Trapping Device,” Analytical Chemistry 92, no. 15 (2020): 10733-10742.

[139] Y. Chen, Q. Zhu, L. Cheng, et al., “Exosome Detection via the Ultrafast-Isolation System: EXODUS,” Nature Methods 18, no. 2 (2021): 212-218.

[140] Q. Yang, L. Cheng, L. Hu, et al., “An Integrative Microfluidic Device for Isolation and Ultrasensitive Detection of Lung Cancer-Specific Exosomes From Patient Urine,” Biosensors & Bioelectronics 163, no. 1 (2020): 112290.

[141] X. Hua, Q. Zhu, Y. Liu, et al., “A Double Tangential Flow Filtration-Based Microfluidic Device for Highly Efficient Separation and Enrichment of Exosomes,” Analytica Chimica Acta 1258, no. 2 (2023): 341160.

[142] G. Li, W. Tang, and F. Yang, “Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms,” Biotechnology Journal 15, no. 5 (2020): e1900174.

[143] J. A. Welsh, D. C. I. Goberdhan, and L. O'Driscoll, “Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches (vol 13, e12404, 2023),” Journal of Extracellular Vesicles 13, no. 5 (2024): 12404.

[144] S. Ahmadian, N. Jafari, A. Tamadon, et al., “Different Storage and Freezing Protocols for Extracellular Vesicles: A Systematic Review,” Stem Cell Research & Therapy 15, no. 1 (2024): 453.

[145] M. Li, “Atomic Force Microscopy as a Nanomechanical Tool for Cancer Liquid Biopsy,” Biochemical and Biophysical Research Communications 734, no. 1 (2024): 150637.

[146] A. M. Aresta, N. De Vietro, and C. Zambonin, “Analysis and Characterization of the Extracellular Vesicles Released in Non-Cancer Diseases Using Matrix-Assisted Laser Desorption Ionization/Mass Spectrometry,” International Journal of Molecular Sciences 25, no. 8 (2024): 4490.

[147] G. Kowkabany and Y. Bao, “Nanoparticle Tracking Analysis: An Effective Tool to Characterize Extracellular Vesicles,” Molecules (Basel, Switzerland) 29, no. 19 (2024): 4672.

[148] A. D. Kashkanova, D. Albrecht, M. Kueppers, M. Blessing, and V. Sandoghdar, “Measuring Concentration of Nanoparticles in Polydisperse Mixtures Using Interferometric Nanoparticle Tracking Analysis,” ACS Nano 18, no. 29 (2024): 19161-19168.

[149] M. R. C. Calado, T. C. Lage, D. A. M. Andre, et al., “Nanofluidic Resistive Pulse Sensing for Characterization of Extracellular Vesicles,” Lab on A Chip 24, no. 17 (2024): 221.

[150] T. S. Lyu, Y. Ahn, Y.-J. Im, et al., “The Characterization of Exosomes From Fibrosarcoma Cell and the Useful Usage of Dynamic Light Scattering (DLS) for Their Evaluation,” PLoS ONE 16, no. 1 (2021): e0259508.

[151] K. E. Thane, A. M. Davis, and A. M. Hoffman, “Improved Methods for Fluorescent Labeling and Detection of Single Extracellular Vesicles Using Nanoparticle Tracking Analysis,” Scientific Reports 9, no. 12 (2019): 12295.

[152] L. Perpetuo, R. Ferreira, V. Thongboonkerd, et al., “Urinary Exosomes: Diagnostic Impact With a Bioinformatic Approach,” Advances in Clinical Chemistry 111, no. 1 (2022): 69-99.

[153] N. Koliha, Y. Wiencek, U. Heider, et al., “A Novel Multiplex Bead-Based Platform Highlights the Diversity of Extracellular Vesicles,” Journal of Extracellular Vesicles 5, no. 1 (2016): 29975.

[154] A. Morales-Kastresana, T. A. Musich, J. A. Welsh, et al., “High-Fidelity Detection and Sorting of Nanoscale Vesicles in Viral Disease and Cancer,” Journal of Extracellular Vesicles 8, no. 1 (2019): 1597603.

[155] E. J. K. Kowal, D. Ter-Ovanesyan, A. Regev, and G. M. Church, “Extracellular Vesicle Isolation and Analysis by Western Blotting,” Methods in Molecular Biology 1660, no. 6 (2017): 143-152.

[156] V. Pospichalova, J. Svoboda, Z. Dave, et al., “Simplified Protocol for Flow Cytometry Analysis of Fluorescently Labeled Exosomes and Microvesicles Using Dedicated Flow Cytometer,” Journal of Extracellular Vesicles 4, no. 9 (2015): 25530-25530.

[157] P. Tyagi, D. Singh, S. Mathur, A. Singh, and R. Ranjan, “Upcoming Progress of Transcriptomics Studies on Plants: An Overview,” Frontiers in Plant Science 13, no. 1 (2022): 802205.

[158] P. Pousinis, I. R. Ramos, M. N. Woodroofe, and L. M. Cole, “Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis,” Metabolites 10, no. 9 (2020): 366.

[159] J. K. Patra, G. Das, L. F. Fraceto, et al., “Nano Based Drug Delivery Systems: Recent Developments and Future Prospects,” Journal of Nanbiotechnology 16, no. 7 (2018): 69.

[160] J. Lee, J.-H. Lee, K. Chakraborty, J. Hwang, and Y.-K. Lee, “Exosome-Based Drug Delivery Systems and Their Therapeutic Applications,” RSC Advances 12, no. 29 (2022): 18475-18492.

[161] Q. Huo, Y. Shi, Y. Qi, et al., “Biomimetic Silibinin-Loaded Macrophage-Derived Exosomes Induce Dual Inhibition of Aβ Aggregation and Astrocyte Activation to Alleviate Cognitive Impairment in a Model of Alzheimer's Disease,” Mater Sci Eng C Mater Biol Appl 129, no. 6 (2021): 112365.

[162] N. Shrestha, Y. Xu, J. R. C. Prevost, et al., “Impact of PEGylation on an Antibody-Loaded Nanoparticle-Based Drug Delivery System for the Treatment of Inflammatory Bowel Disease,” Acta Biomaterialia 140, no. 1 (2022): 561-572.

[163] Y. Liu, N. Fu, J. Su, X. Wang, and X. Li, “Rapid Enkephalin Delivery Using Exosomes to Promote Neurons Recovery in Ischemic Stroke by Inhibiting Neuronal p53/Caspase-3,” BioMed Research International 2019, no. 1 (2019): 8274319.

[164] A. K. Roghani, R. I. Garcia, A. Roghani, et al., “Treating Alzheimer's Disease Using Nanoparticle-Mediated Drug Delivery Strategies/Systems,” Ageing Research Reviews 97, no. 1 (2024): 102291.

[165] A. Iyaswamy, A. Thakur, X.-J. Guan, et al., “Fe65-Engineered Neuronal Exosomes Encapsulating Corynoxine-B Ameliorate Cognition and Pathology of Alzheimer's Disease,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 160.

[166] T. Tian, H.-X. Zhang, C.-P. He, et al., “Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy,” Biomaterials 150, no. 2 (2018): 137-149.

[167] K. W. Witwer and J. Wolfram, “Extracellular Vesicles Versus Synthetic Nanoparticles for Drug Delivery,” Nature Reviews Materials 6, no. 2 (2021): 103-106.

[168] H. Y. Kim, T. J. Kim, L. Kang, et al., “Mesenchymal Stem Cell-Derived Magnetic Extracellular Nanovesicles for Targeting and Treatment of Ischemic Stroke,” Biomaterials 243, no. 1 (2020): 119942.

[169] F. Xu, Y. Wu, Q. Yang, et al., “Engineered Extracellular Vesicles With SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment,” Advanced Materials 34, no. 49 (2022): 2202583.

[170] M. Qu, Q. Lin, L. Huang, et al., “Dopamine-Loaded Blood Exosomes Targeted to Brain for Better Treatment of Parkinson's Disease,” Journal of Controlled Release 287, no. 8 (2018): 156-166.

[171] J. Yang, S. Luo, J. Zhang, et al., “Exosome-Mediated Delivery of Antisense Oligonucleotides Targeting α-Synuclein Ameliorates the Pathology in a Mouse Model of Parkinson's Disease,” Neurobiology of Disease 148, no. 1 (2021): 105218.

[172] L. Zhang, T. Wu, Y. Shan, et al., “Therapeutic Reversal of Huntington's Disease by in Vivo Self-Assembled siRNAs,” Brain 144, no. 1 (2021): 3421-3435.

[173] H. Wang, H. Sui, Y. Zheng, et al., “Curcumin-Primed Exosomes Potently Ameliorate Cognitive Function in AD Mice by Inhibiting Hyperphosphorylation of the Tau Protein Through the AKT/GSK-3β Pathway,” Nanoscale 11, no. 15 (2019): 7481-7496.

[174] M. Mobahat, E. Sadroddiny, V. T. Nooshabadi, et al., “Curcumin-Loaded Human Endometrial Stem Cells Derived Exosomes as an Effective Carrier to Suppress Alpha-Synuclein Aggregates in 6OHDA-Induced Parkinson's Disease Mouse Model,” Cell and Tissue Banking 24, no. 1 (2023): 75-91.

[175] Y. Wang, M. Jiang, X. Zheng, et al., “Application of Exosome Engineering Modification in Targeted Delivery of Therapeutic Drugs,” Biochemical Pharmacology 215, no. 1 (2023): 115691.

[176] V. Varshney, B. C. Gabble, A. K. Bishoyi, et al., “Exploring Exosome-Based Approaches for Early Diagnosis and Treatment of Neurodegenerative Diseases,” Molecular Neurobiology 7, no. 1 (2025): 786.

[177] N. Sayeed and K. Sugaya, “Exosome Mediated Tom40 Delivery Protects Against Hydrogen Peroxide-Induced Oxidative Stress by Regulating Mitochondrial Function,” PLoS ONE 17, no. 8 (2022): e0273571.

[178] J. Li, J. Wang, and Z. Chen, “Emerging Role of Exosomes in Cancer Therapy: Progress and Challenges,” Molecular Cancer 24, no. 1 (2025): 13.

[179] Y. Jahangard, H. Monfared, A. Moradi, et al., “Therapeutic Effects of Transplanted Exosomes Containing miR-29b to a Rat Model of Alzheimer's Disease,” Frontiers in Neuroscience 14, no. 1 (2020): 564.

[180] Y.-Q. Lin, K.-K. Feng, J.-Y. Lu, et al., “CRISPR/Cas9-Based Application for Cancer Therapy: Challenges and Solutions for Non-Viral Delivery,” Journal of Controlled Release 361, no. 1 (2023): 727-749.

[181] Y. Ye, Q. Shi, T. Yang, et al., “In Vivo Visualized Tracking of Tumor-Derived Extracellular Vesicles Using CRISPR-Cas9 System,” Technology in Cancer Research & Treatment 21, no. 1 (2022): 85370.

[182] R. He, Y. Jiang, Y. Shi, J. Liang, and L. Zhao, “Curcumin-Laden Exosomes Target Ischemic Brain Tissue and Alleviate Cerebral Ischemia-Reperfusion Injury by Inhibiting ROS-Mediated Mitochondrial Apoptosis,” Mater Sci Eng C Mater Biol Appl 117, no. 10 (2020): 111314.

[183] U. Altanerova, M. Babincova, P. Babinec, et al., “Human Mesenchymal Stem Cell-Derived Iron Oxide Exosomes Allow Targeted Ablation of Tumor Cells via Magnetic Hyperthermia,” International Journal of Nanomedicine 12, no. 6 (2017): 7923-7936.

[184] X. Ge, M. Guo, T. Hu, et al., “Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome After rmTBI,” Molecular Therapy 28, no. 2 (2020): 503-522.

[185] M. Morishita, Y. Takahashi, A. Matsumoto, M. Nishikawa, and Y. Takakura, “Exosome-Based Tumor Antigens-Adjuvant Co-Delivery Utilizing Genetically Engineered Tumor Cell-Derived Exosomes With Immunostimulatory CpG DNA,” Biomaterials 111, no. 1 (2016): 55-65.

[186] O. Park, E. S. Choi, G. Yu, et al., “Efficient Delivery of Tyrosinase Related Protein-2 (TRP2) Peptides to Lymph Nodes Using Serum-Derived Exosomes,” Macromolecular Bioscience 18, no. 12 (2018): 1070177.

[187] S. Pan, L. Pei, A. Zhang, et al., “Passion Fruit-Like Exosome-PMA/Au-BSA@Ce6 Nanovehicles for Real-Time Fluorescence Imaging and Enhanced Targeted Photodynamic Therapy With Deep Penetration and Superior Retention Behavior in Tumor,” Biomaterials 230, no. 4 (2020): 119606.

[188] D. N. Kumar, A. Chaudhuri, D. Kumar, S. Singh, and A. K. Agrawal, “Impact of the Drug Loading Method on the Drug Distribution and Biological Efficacy of Exosomes,” Aaps Pharmscitech [Electronic Resource] 24, no. 6 (2023): 166.

[189] M. S. Kim, M. J. Haney, Y. Zhao, et al., “Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells,” Nanomedicine (Lond) 12, no. 3 (2016): 655-664.

[190] J. Wang, D. Chen, and E. A. Ho, “Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems,” Journal of Controlled Release 329, no. 1 (2021): 894-906.

[191] G. R. Gunassekaran, S. M. P. Vadevoo, M.-C. Baek, and B. Lee, “M1 Macrophage Exosomes Engineered to Foster M1 Polarization and Target the IL-4 Receptor Inhibit Tumor Growth by Reprogramming Tumor-Associated Macrophages Into M1-Like Macrophages,” Biomaterials 278, no. 8 (2021): 121137.

[192] A. N. Kenari, L. Cheng, and A. F. Hill, “Methods for Loading Therapeutics Into Extracellular Vesicles and Generating Extracellular Vesicles Mimetic-Nanovesicles,” Methods (San Diego, Calif.) 177, no. 11 (2020): 103-113.

[193] M. J. Haney, Y. Zhao, Y. S. Jin, et al., “Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy,” J Neuroimmune Pharmacol 15, no. 3 (2020): 487-500.

[194] H. Chen, L. Wang, X. Zeng, et al., “Exosomes, a New Star for Targeted Delivery,” Frontiers in Cell and Developmental Biology 9, no. 5 (2021): 751079.

[195] Z. Chen, M. Xiong, J. Tian, et al., “Encapsulation and Assessment of Therapeutic Cargo in Engineered Exosomes: A Systematic Review,” Journal of Nanbiotechnology 22, no. 1 (2024): 18.

[196] Z. Nouri, A. Barfar, S. Perseh, et al., “Exosomes as Therapeutic and Drug Delivery Vehicle for Neurodegenerative Diseases,” Journal of Nanbiotechnology 22, no. 1 (2024): 463.

[197] Y.-N. Ma, X. Hu, and K. Karako, “Exploring the Multiple Therapeutic Mechanisms and Challenges of Mesenchymal Stem Cell-Derived Exosomes in Alzheimer's Disease,” Biosci Trends 18, no. 5 (2024): 413-430.

[198] S. Zhang, Y. Yang, X. Lv, et al., “Exosome Cargo in Neurodegenerative Diseases: Leveraging Their Intercellular Communication Capabilities for Biomarker Discovery and Therapeutic Delivery,” Brain Sciences 14, no. 11 (2024): 1049.

[199] A. Luarte, L. Federico Batiz, U. Wyneken, and C. Lafourcade, “Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche,” Stem Cells International 2016, no. 6 (2016): 5736059.

[200] S. Zhao, Y. Di, H. Fan, et al., “Targeted Delivery of Extracellular Vesicles: The Mechanisms, Techniques and Therapeutic Applications,” Molecular Biomedicine 5, no. 1 (2024): 60-60.

[201] Q. Yang, S. Li, H. Ou, et al., “Exosome-Based Delivery Strategies for Tumor Therapy: An Update on Modification, Loading, and Clinical Application,” Journal of Nanbiotechnology 22, no. 1 (2024): 41.

[202] Y. Yu, W. Li, L. Mao, et al., “Genetically Engineered Exosomes Display RVG Peptide and Selectively Enrich a Neprilysin Variant: A Potential Formulation for the Treatment of Alzheimer's Disease,” Journal of Drug Targeting 29, no. 10 (2021): 1128-1138.

[203] Y. Yue, W. Dai, Y. Wei, et al., “Unlocking the Potential of Exosomes: A Breakthrough in the Theranosis of Degenerative Orthopaedic Diseases,” Frontiers in Bioengineering and Biotechnology 12, no. 1 (2024): 1377142.

[204] N. Kucuk, M. Primozic, Z. Knez, and M. Leitgeb, “Exosomes Engineering and Their Roles as Therapy Delivery Tools, Therapeutic Targets, and Biomarkers,” International Journal of Molecular Sciences 22, no. 17 (2021): 9543.

[205] C. Si, J. Gao, and X. Ma, “Engineered Exosomes in Emerging Cell-Free Therapy,” Frontiers in Oncology 14, no. 1 (2024): 1382398.

[206] Q. Wang, T. Li, J. Yang, et al., “Engineered Exosomes With Independent Module/Cascading Function for Therapy of Parkinson's Disease by Multistep Targeting and Multistage Intervention Method,” Advanced Materials 34, no. 27 (2022): 2106611.

[207] Y. Yang, Y. Hong, E. Cho, G. B. Kim, and I.-S. Kim, “Extracellular Vesicles as a Platform for Membrane-Associated Therapeutic Protein Delivery,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1440131.

[208] G. Kim, M. Kim, Y. Lee, et al., “Systemic Delivery of microRNA-21 Antisense Oligonucleotides to the Brain Using T7-Peptide Decorated Exosomes,” Journal of Controlled Release 317, no. 1 (2020): 273-281.

[209] Z. Li, X. Zhou, M. Wei, et al., “In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated With miRNA or CRISPR/dCas9,” Nano Letters 19, no. 1 (2019): 19-28.

[210] J. Bai, J. Duan, R. Liu, et al., “Engineered Targeting tLyp-1 Exosomes as Gene Therapy Vectors for Efficient Delivery of siRNA Into Lung Cancer Cells,” Asian Journal of Pharmaceutical Sciences 15, no. 4 (2020): 461-471.

[211] C. M. Bliss, A. J. Parsons, R. Nachbagauer, et al., “Targeting Antigen to the Surface of EVs Improves the in Vivo Immunogenicity of Human and Non-Human Adenoviral Vaccines in Mice,” Molecular Therapy Methods & Clinical Development 16, no. 9 (2020): 108-125.

[212] X. Shi, Q. Cheng, T. Hou, et al., “Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy,” Molecular Therapy 28, no. 2 (2020): 536-547.

[213] H. Choi, Y. Choi, H. Y. Yim, et al., “Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes,” Tissue Engineering and Regenerative Medicine 18, no. 4 (2021): 499-511.

[214] G. Jia, Y. Han, Y. An, et al., “NRP-1 Targeted and Cargo-Loaded Exosomes Facilitate Simultaneous Imaging and Therapy of Glioma in Vitro and in Vivo,” Biomaterials 178, no. 6 (2018): 302-316.

[215] M. S. Kim, M. J. Haney, Y. Zhao, et al., “Engineering Macrophage-Derived Exosomes for Targeted Paclitaxel Delivery to Pulmonary Metastases: In Vitro and in Vivo Evaluations,” Nanomedicine (Lond) 14, no. 1 (2018): 195-204.

[216] H. Qi, C. Liu, L. Long, et al., “Blood Exosomes Endowed With Magnetic and Targeting Properties for Cancer Therapy,” ACS Nano 10, no. 3 (2016): 3323-3333.

[217] E. S. Choi, J. Song, Y. Y. Kang, and H. Mok, “Mannose-Modified Serum Exosomes for the Elevated Uptake to Murine Dendritic Cells and Lymphatic Accumulation,” Macromolecular Bioscience 19, no. 7 (2019): e1900049.

[218] S. A. Dusoswa, S. K. Horrevorts, M. Ambrosini, et al., “Glycan Modification of Glioblastoma-Derived Extracellular Vesicles Enhances Receptor-Mediated Targeting of Dendritic Cells,” Journal of Extracellular Vesicles 8, no. 1 (2019): 1648995.

[219] I. Nakase and S. Futaki, “Combined Treatment With a pH-Sensitive Fusogenic Peptide and Cationic Lipids Achieves Enhanced Cytosolic Delivery of Exosomes,” Scientific Reports 5, no. 2 (2015): 10112.

[220] R. Tamura, S. Uemoto, and Y. Tabata, “Augmented Liver Targeting of Exosomes by Surface Modification With Cationized Pullulan,” Acta Biomaterialia 57, no. 4 (2017): 274-284.

[221] A. Vandergriff, K. Huang, D. Shen, et al., “Targeting Regenerative Exosomes to Myocardial Infarction Using Cardiac Homing Peptide,” Theranostics 8, no. 7 (2018): 1869-1878.

[222] J. Wang, W. Li, Z. Lu, et al., “The Use of RGD-Engineered Exosomes for Enhanced Targeting Ability and Synergistic Therapy Toward Angiogenesis,” Nanoscale 9, no. 40 (2017): 15598-15605.

[223] Y. T. Sato, K. Umezaki, S. Sawada, et al., “Engineering Hybrid Exosomes by Membrane Fusion With Liposomes,” Scientific Reports 6, no. 4 (2016): 21933.

[224] J. Lee, H. Lee, U. Goh, et al., “Cellular Engineering With Membrane Fusogenic Liposomes to Produce Functionalized Extracellular Vesicles,” ACS Appl Mater Interfaces 8, no. 11 (2016): 6790-6795.

[225] M. Zhuang, D. Du, L. Pu, et al., “SPION-Decorated Exosome Delivered BAY55-9837 Targeting the Pancreas Through Magnetism to Improve the Blood GLC Response,” Small 15, no. 52 (2019): e1903135.

[226] X. Luan, K. Sansanaphongpricha, I. Myers, et al., “Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery,” Acta Pharmaceutica Sinica B 38, no. 6 (2017): 754-763.

[227] N. Fayazi, M. Sheykhhasan, S. Soleimani Asl, and R. Najafi, “Stem Cell-Derived Exosomes: A New Strategy of Neurodegenerative Disease Treatment,” Molecular Neurobiology 58, no. 7 (2021): 3494-3514.

[228] M. Ullah, D. D. Liu, and A. S. Thakor, “Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement,” Iscience 15, no. 2 (2019): 421-438.

[229] A. C. Matei, L. Antounians, and A. Zani, “Extracellular Vesicles as a Potential Therapy for Neonatal Conditions: State of the Art and Challenges in Clinical Translation,” Pharmaceutics 11, no. 8 (2019): 404.

[230] X.-L. Fan, Y. Zhang, X. Li, and Q.-L. Fu, “Mechanisms Underlying the Protective Effects of Mesenchymal Stem Cell-Based Therapy,” Cellular and Molecular Life Sciences 77, no. 14 (2020): 2771-2794.

[231] K. Kisler, A. R. Nelson, A. Montagne, and B. V. Zlokovic, “Cerebral Blood Flow Regulation and Neurovascular Dysfunction in Alzheimer Disease,” Nature Reviews Neuroscience 18, no. 7 (2017): 419-434.

[232] B. Sethi, V. Kumar, K. Mahato, D. W. Coulter, and R. I. Mahato, “Recent Advances in Drug Delivery and Targeting to the Brain,” Journal of Controlled Release 350, no. 3 (2022): 668-687.

[233] T.-T. Zhang, W. Li, G. Meng, P. Wang, and W. Liao, “Strategies for Transporting Nanoparticles Across the Blood-Brain Barrier,” Biomaterials Science 4, no. 2 (2016): 219-229.

[234] E. S. Lippmann, S. M. Azarin, J. E. Kay, et al., “Derivation of Blood-Brain Barrier Endothelial Cells From Human Pluripotent Stem Cells,” Nature Biotechnology 30, no. 8 (2012): 783-791.

[235] C. E. Hansen, D. Hollaus, A. Kamermans, and H. E. de Vries, “Tension at the Gate: Sensing Mechanical Forces at the Blood-Brain Barrier in Health and Disease,” Journal of Neuroinflammation 21, no. 1 (2024): 325.

[236] X. Li, Z. Han, T. Wang, et al., “Cerium Oxide Nanoparticles With Antioxidative Neurorestoration for Ischemic Stroke,” Biomaterials 291, no. 5 (2022): 121904.

[237] C. M. Weber, B. Moiz, and A. M. Clyne, “Brain Microvascular Endothelial Cell Metabolism and Its Ties to Barrier Function,” Vitamins and Hormones 126, no. 1 (2024): 25-75.

[238] X. Zheng, B. Ren, and Y. Gao, “Tight Junction Proteins Related to Blood-Brain Barrier and Their Regulatory Signaling Pathways in Ischemic Stroke,” Biomedicine & Pharmacotherapy 165, no. 1 (2023): 115272.

[239] E. Hanael, S. Baruch, R. K. Altman, et al., “Blood-Brain Barrier Dysfunction and Decreased Transcription of Tight Junction Proteins in Epileptic Dogs,” Journal of Veterinary Internal Medicine 38, no. 4 (2024): 2237-2248.

[240] H. Alluri, C. S. Peddaboina, and B. Tharakan, “Determination of Tight Junction Integrity in Brain Endothelial Cells Based on Tight Junction Protein Expression,” Methods in Molecular Biology 2711, no. 1 (2024): 235-240.

[241] A. R. Santa-Maria, F. R. Walter, R. Figueiredo, et al., “Flow Induces Barrier and Glycocalyx-Related Genes and Negative Surface Charge in a Lab-on-a-Chip Human Blood-Brain Barrier Model,” Journal of Cerebral Blood Flow and Metabolism 41, no. 9 (2021): 2201-2215.

[242] Y. Zhao, Y. Liu, Y. Xu, et al., “The Role of Ferroptosis in Blood-Brain Barrier Injury,” Cellular and Molecular Neurobiology 43, no. 1 (2023): 223-236.

[243] L. E. Takeuchi, L. V. Kalia, and C. A. Simmons, “Vascular Models of Alzheimer's Disease: An Overview of Recent in Vitro Models of the Blood-Brain Barrier,” Neurobiology of Disease 208, no. 1 (2025): 106864.

[244] S. Kawakita, K. Mandal, L. Mou, et al., “Organ-On-A-Chip Models of the Blood-Brain Barrier: Recent Advances and Future Prospects,” Small 18, no. 39 (2022): 2201401.

[245] A. Nasrollahi and Y. Yao, “Laminins and the Blood-Brain Barrier,” Matrix Biology 137, no. 1 (2025): 33-41.

[246] I. Koh and M. Hagiwara, “Modular Tissue-in-a-CUBE Platform to Model Blood-Brain Barrier (BBB) and Brain Interaction,” Communications Biology 7, no. 1 (2024): 177.

[247] Y. A. Divecha, S. Rampes, S. Tromp, et al., “The Microcirculation, the Blood-Brain Barrier, and the Neurovascular Unit in Health and Alzheimer Disease: The Aberrant Pericyte is a Central Player,” Pharmacological Reviews 77, no. 3 (2025): 100052.

[248] J. Frosen and A. Joutel, “Smooth Muscle Cells of Intracranial Vessels: From Development to Disease,” Cardiovascular Research 114, no. 4 (2018): 501-512.

[249] S. J. Pfau, U. H. Langen, T. M. Fisher, et al., “Characteristics of Blood-Brain Barrier Heterogeneity Between Brain Regions Revealed by Profiling Vascular and Perivascular Cells,” Nature Neuroscience 27, no. 10 (2024): 1892-1903.

[250] M. J. Stebbins, B. D. Gastfriend, S. G. Canfield, et al., “Human Pluripotent Stem Cell-Derived Brain Pericyte-Like Cells Induce Blood-Brain Barrier Properties,” Science Advances 5, no. 3 (2019): 7375.

[251] A. I. Beltran-Velasco and V. J. Clemente-Suarez, “Impact of Peripheral Inflammation on Blood-Brain Barrier Dysfunction and Its Role in Neurodegenerative Diseases,” International Journal of Molecular Sciences 26, no. 6 (2025): 2440.

[252] H. Yuan, D. Sun, Y. Ji, et al., “Pericyte Loss Impairs the Blood-Brain Barrier and Cognitive Function in Aged Mice After Anesthesia/Surgery,” Brain Research Bulletin 204, no. 1 (2023): 110799.

[253] W. M. Zhu, A. Neuhaus, D. J. Beard, B. A. Sutherland, and G. C. DeLuca, “Neurovascular Coupling Mechanisms in Health and Neurovascular Uncoupling in Alzheimer's Disease,” Brain 145, no. 7 (2022): 2276-2292.

[254] Z. Li, X. Hou, Y. Lu, et al., “Functional MRI Study of Neurovascular Coupling in Patients With Non-Lesional Epilepsy,” Frontiers in Human Neuroscience 18, no. 1 (2025): 1517565.

[255] D. Ma, Q. Li, and H. Zhang, “Vascular Smooth Muscle Cell Dysfunction in Cerebral Small Vessel Disease: Mechanisms and Therapeutic Potential,” Cerebrovascular Diseases 10, no. 1 (2025): 1-11.

[256] F. Endo, A. Kasai, J. S. Soto, et al., “Molecular Basis of Astrocyte Diversity and Morphology Across the CNS in Health and Disease,” Science 378, no. 6619 (2022): 514-525.

[257] Y. Yuan, H. Liu, Z. Dai, et al., “From Physiology to Pathology of Astrocytes: Highlighting Their Potential as Therapeutic Targets for CNS Injury,” Neuroscience Bulletin 41, no. 1 (2025): 131-154.

[258] R. Lv, B. Liu, Z. Jiang, et al., “Intermittent Fasting and Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Potential,” Metabolism 164, no. 1 (2025): 156104.

[259] S. A. Sonar and G. Lal, “Blood-Brain Barrier and Its Function During Inflammation and Autoimmunity,” Journal of Leukocyte Biology 103, no. 5 (2018): 839-853.

[260] N. Ahmadpour, M. Kantroo, and J. L. Stobart, “Extracellular Calcium Influx Pathways in Astrocyte Calcium Microdomain Physiology,” Biomolecules 11, no. 10 (2021): 1467.

[261] H. L. McConnell and A. Mishra, “Cells of the Blood-Brain Barrier: An Overview of the Neurovascular Unit in Health and Disease,” Methods in Molecular Biology 2492, no. 6 (2022): 3-24.

[262] J. Zhao, J. Sun, Y. Zheng, et al., “Activated Astrocytes Attenuate Neocortical Seizures in Rodent Models Through Driving Na-ATPase,” Nature Communications 13, no. 1 (2022): 7136.

[263] A. F. Sobral, I. Costa, V. Teixeira, R. Silva, and D. J. Barbosa, “Molecular Motors in Blood-Brain Barrier Maintenance by Astrocytes,” Brain Sciences 15, no. 3 (2025): 279.

[264] S. Sriram, K. Carstens, W. Dewing, and T. A. Fiacco, “Astrocyte Regulation of Extracellular Space Parameters Across the Sleep-Wake Cycle,” Frontiers in Cellular Neuroscience 18, no. 1 (2024): 1401698.

[265] C. Pallares-Moratalla and G. Bergers, “The Ins and Outs of Microglial Cells in Brain Health and Disease,” Frontiers in Immunology 15, no. 1 (2024): 1305087.

[266] M. S. Thion, F. Ginhoux, and S. Garel, “Microglia and Early Brain Development: An Intimate Journey,” Science 362, no. 6411 (2018): 185-189.

[267] U. B. Eyo and L.-J. Wu, “Microglia: Lifelong Patrolling Immune Cells of the Brain,” Progress in Neurobiology 179, no. 6 (2019): 101614.

[268] M. Sadeghdoust, A. Das, and D. K. Kaushik, “Fueling Neurodegeneration: Metabolic Insights Into Microglia Functions,” Journal of Neuroinflammation 21, no. 1 (2024): 300.

[269] L. Michalick, “Macrophage Plasticity-A Matter of Timing and Mechanical Load,” Acta Physiologica 237, no. 4 (2023): 13954.

[270] H. Van Hove, C. Gluck, W. Mildenberger, et al., “Interleukin-34-Dependent Perivascular Macrophages Promote Vascular Function in the Brain,” Immunity 58, no. 5 (2025): P1289-1305.

[271] A. O. Lopez-Ortiz and U. B. Eyo, “Astrocytes and Microglia in the Coordination of CNS Development and Homeostasis,” Journal of Neurochemistry 168, no. 10 (2024): 3599-3614.

[272] N. Huebel, E. Schoell, and M. A. Dahlem, “Bistable Dynamics Underlying Excitability of Ion Homeostasis in Neuron Models,” PLOS Computational Biology 10, no. 5 (2014): e1003551.

[273] R. S. Pulido, R. N. Munji, T. C. Chan, et al., “Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport Through Endothelial Circadian Genes,” Neuron 108, no. 5 (2020): 937-952.

[274] M. J. Reed, M. Damodarasamy, and W. A. Banks, “The Extracellular Matrix of the Blood-Brain Barrier: Structural and Functional Roles in Health, Aging, and Alzheimer's Disease,” Tissue Barriers 7, no. 4 (2019): 1651157-1651157.

[275] J. Sun, M. Wang, L. Guo, et al., “Protective Effect of Brain Microvascular Endothelial Cell-Derived Exosomes on Blood-Brain Barrier Induced by Ischemia-Reperfusion Injury in Vivo and in Vitro,” Frontiers in Pharmacology 16, no. 1 (2025): 1548122.

[276] Y. Zabrodskaya, N. Paramonova, A. Litovchenko, et al., “Neuroinflammatory Dysfunction of the Blood-Brain Barrier and Basement Membrane Dysplasia Play a Role in the Development of Drug-Resistant Epilepsy,” International Journal of Molecular Sciences 24, no. 16 (2023): 12689.

[277] M. S. Thomsen, S. Birkelund, A. Burkhart, A. Stensballe, and T. Moos, “Synthesis and Deposition of Basement Membrane Proteins by Primary Brain Capillary Endothelial Cells in a Murine Model of the Blood-Brain Barrier,” Journal of Neurochemistry 140, no. 5 (2017): 741-754.

[278] E. Benarroch, “What Are the Roles of Pericytes in the Neurovascular Unit and Its Disorders?,” Neurology 100, no. 20 (2023): 970-977.

[279] J. Matsumoto, T. Stewart, W. A. Banks, and J. Zhang, “The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier,” Current Pharmaceutical Design 23, no. 40 (2017): 6206-6214.

[280] J. Saint-Pol, F. Gosselet, S. Duban-Deweer, G. Pottiez, and Y. Karamanos, “Targeting and Crossing the Blood-Brain Barrier With Extracellular Vesicles,” Cells 9, no. 4 (2020): 851.

[281] M. P. Bebelman, C. Crudden, D. M. Pegtel, and M. J. Smit, “The Convergence of Extracellular Vesicle and GPCR Biology,” Trends in Pharmacological Sciences 41, no. 9 (2020): 627-640.

[282] H. M. Ramos-Zaldivar, I. Polakovicova, E. Salas-Huenuleo, et al., “Extracellular Vesicles Through the Blood-Brain Barrier: A Review,” Fluids Barriers CNS 19, no. 1 (2022): 60.

[283] M. Abdelsalam, M. Ahmed, Z. Osaid, R. Hamoudi, and R. Harati, “Insights Into Exosome Transport Through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases,” Pharmaceuticals 16, no. 4 (2023): 571.

[284] H. Choi, K. Choi, D.-H. Kim, et al., “Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges,” Pharmaceutics 14, no. 3 (2022): 672.

[285] W. A. Banks, P. Sharma, K. M. Bullock, et al., “Transport of Extracellular Vesicles Across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation,” International Journal of Molecular Sciences 21, no. 12 (2020): 4407.

[286] Z. Zhao and B. V. Zlokovic, “Remote Control of BBB: A Tale of Exosomes and microRNA,” Cell Research 27, no. 7 (2017): 849-850.

[287] J. Cui, X. Wang, J. Li, et al., “Immune Exosomes Loading Self-Assembled Nanomicelles Traverse the Blood-Brain Barrier for Chemo-Immunotherapy Against Glioblastoma,” ACS Nano 17, no. 2 (2023): 1464-1484.

[288] N. Chen, Y. He, M. Zang, et al., “Approaches and Materials for Endocytosis-Independent Intracellular Delivery of Proteins,” Biomaterials 286, no. 1 (2022): 121567.

[289] Y. van der Merwe and M. B. Steketee, “Extracellular Vesicles: Biomarkers, Therapeutics, and Vehicles in the Visual System,” Current Ophthalmology Reports 5, no. 4 (2017): 276-282.

[290] S. Edavettal, P. Cejudo-Martin, B. Dasgupta, et al., “Enhanced Delivery of Antibodies Across the Blood-Brain Barrier via TEMs With Inherent Receptor-Mediated Phagocytosis,” Med (N Y) 3, no. 12 (2022): 860-882.

[291] M. Abrishamdar, M. S. Jalali, and N. Yazdanfar, “The Role of Exosomes in Pathogenesis and the Therapeutic Efficacy of Mesenchymal Stem Cell-Derived Exosomes Against Parkinson's Disease,” Neurological Sciences 44, no. 7 (2023): 2277-2289.

[292] Y. T. Sato, K. Umezaki, S. Sawada, et al., “Engineering Hybrid Exosomes by Membrane Fusion With Liposomes,” Scientific Reports 6, no. 1 (2016): 21933.

[293] M. Xu, J. Ji, and D. Jin, “The Biogenesis and Secretion of Exosomes and Multivesicular Bodies (MVBs): Intercellular Shuttles and Implications in Human Diseases,” Genes & Diseases 10, no. 5 (2023): 1894-1907.

[294] S. Ghadami and K. Dellinger, “The Lipid Composition of Extracellular Vesicles: Applications in Diagnostics and Therapeutic Delivery,” Frontiers in Molecular Biosciences 10, no. 1 (2023): 1198044.

[295] J. Li, M. Zheng, O. Shimoni, et al., “Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier,” Advanced Science (Weinh) 8, no. 16 (2021): 2101090.

[296] C. Li, S. Qin, Y. Wen, et al., “Overcoming the Blood-Brain Barrier: Exosomes as Theranostic Nanocarriers for Precision Neuroimaging,” Journal of Controlled Release 349, no. 1 (2022): 902-916.

[297] L. Thieren, H. S. Zanker, J. Droux, et al., “Astrocytic GLUT1 Deletion in Adult Mice Enhances Glucose Metabolism and Resilience to Stroke,” Nature Communications 16, no. 1 (2025): 4190.

[298] S. T. Boyanova, E. Lloyd-Morris, C. Corpe, et al., “Interaction of Amisulpride With GLUT1 at the Blood-Brain Barrier. Relevance to Alzheimer's Disease,” PLoS ONE 18, no. 10 (2023): e0286278-e0286278.

[299] H. S. Ahmed, “The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential,” Molecular Neurobiology 62, no. 3 (2025): 3813-3832.

[300] A. B. Montaser, J. Jarvinen, S. Loffler, et al., “L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug Across the Blood-Brain Barrier and Into Human and Mouse Brain Parenchymal Cells,” ACS Chemical Neuroscience 11, no. 24 (2020): 4301-4315.

[301] F. U. Rehman, Y. Liu, M. Zheng, and B. Shi, “Exosomes Based Strategies for Brain Drug Delivery,” Biomaterials 293, no. 1 (2023): 121949.

[302] H. Tao and B. Gao, “Exosomes for Neurodegenerative Diseases: Diagnosis and Targeted Therapy,” Journal of Neurology 271, no. 6 (2024): 3050-3062.

[303] E. Swissa, Y. Serlin, U. Vazana, O. Prager, and A. Friedmana, “Blood-Brain Barrier Dysfunction in Status Epileptics: Mechanisms and Role in Epileptogenesis,” Epilepsy & Behavior 101, no. 1 (2019): 106285.

[304] D. E. Tylawsky, H. Kiguchi, J. Vaynshteyn, et al., “P-Selectin-Targeted Nanocarriers Induce Active Crossing of the Blood-Brain Barrier via Caveolin-1-Dependent Transcytosis,” Nature Materials 22, no. 3 (2023): 391-399.

[305] M. Jakubec, J. Maple-Grodem, S. Akbari, et al., “Plasma-Derived Exosome-Like Vesicles Are Enriched in Lyso-Phospholipids and Pass the Blood-Brain Barrier,” PLoS ONE 15, no. 9 (2020): e0232442.

[306] C. Yang, Y. Wu, L. Wang, et al., “Glioma-Derived Exosomes Hijack the Blood-Brain Barrier to Facilitate Nanocapsule Delivery via LCN2,” Journal of Controlled Release 345, no. 1 (2022): 537-548.

[307] B. S. Joshi and I. S. Zuhorn, “Heparan Sulfate Proteoglycan-Mediated Dynamin-Dependent Transport of Neural Stem Cell Exosomes in an in Vitro Blood-Brain Barrier Model,” European Journal of Neuroscience 53, no. 3 (2021): 706-719.

[308] D. Yuan, Y. Zhao, W. A. Banks, et al., “Macrophage Exosomes as Natural Nanocarriers for Protein Delivery to Inflamed Brain,” Biomaterials 142, no. 1 (2017): 1-12.

[309] H. Kuroda, M. Tachikawa, Y. Yagi, et al., “Cluster of Differentiation 46 Is the Major Receptor in Human Blood-Brain Barrier Endothelial Cells for Uptake of Exosomes Derived From Brain-Metastatic Melanoma Cells (SK-Mel-28),” Molecular Pharmaceutics 16, no. 1 (2019): 292-304.

[310] L. C. Duke, A. S. Cone, L. Sun, et al., “Tetraspanin CD9 Alters Cellular Trafficking and Endocytosis of Tetraspanin CD63, Affecting CD63 Packaging Into Small Extracellular Vesicles,” Journal of Biological Chemistry 301, no. 3 (2025): 108255.

[311] B. Antonny, S. Vanni, H. Shindou, and T. Ferreira, “From Zero to Six Double Bonds: Phospholipid Unsaturation and Organelle Function,” Trends in Cell Biology 25, no. 7 (2015): 427-436.

[312] M. Bhatta, G. N. Shenoy, J. L. Loyall, et al., “Novel Phosphatidylserine-Binding Molecule Enhances Antitumor T-Cell Responses by Targeting Immunosuppressive Exosomes in Human Tumor Microenvironments,” Journal for ImmunoTherapy of Cancer 9, no. 10 (2021): 3148.

[313] L. Alvarez-Erviti, Y. Seow, H. Yin, et al., “Delivery of siRNA to the Mouse Brain by Systemic Injection of Targeted Exosomes,” Nature Biotechnology 29, no. 4 (2011): 341-345.

[314] M. Grapp, A. Wrede, M. Schweizer, et al., “Choroid Plexus Transcytosis and Exosome Shuttling Deliver Folate Into Brain Parenchyma,” Nature Communications 4, no. 1 (2013): 2123.

[315] C. A. Rene and R. J. Parks, “Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles,” Pharmaceutics 13, no. 4 (2021): 492.

[316] T. G. N. Cao, J. H. Kang, S. J. Kang, et al., “Brain Endothelial Cell-Derived Extracellular Vesicles With a Mitochondria-Targeting Photosensitizer Effectively Treat Glioblastoma by Hijacking the Blood-Brain Barrier,” Acta Pharmaceutica Sinica B 13, no. 9 (2023): 3834-3848.

[317] D. Peng, Y. Wang, Y. Xiao, et al., “Extracellular Vesicles Derived From Astrocyte-Treated With haFGF 14-154 Attenuate Alzheimer Phenotype in AD Mice,” Theranostics 12, no. 8 (2022): 3862-3881.

[318] P. Wang, G. Lan, B. Xu, et al., “α-Synuclein-Carrying Astrocytic Extracellular Vesicles in Parkinson Pathogenesis and Diagnosis,” Translational Neurodegeneration 12, no. 1 (2023): 40.

[319] Y. Zhu, F. Wang, Y. Xia, et al., “Research Progress on Astrocyte-Derived Extracellular Vesicles in the Pathogenesis and Treatment of Neurodegenerative Diseases,” Reviews in the Neurosciences 35, no. 8 (2024): 855-875.

[320] M. Khongkow, T. Yata, S. Boonrungsiman, et al., “Surface Modification of Gold Nanoparticles With Neuron-Targeted Exosome for Enhanced Blood-Brain Barrier Penetration,” Scientific Reports 9, no. 11 (2019): 8278.

[321] Y. Liu, M. Li, J. Gu, et al., “Engineering of Exosome-Liposome Hybrid-Based Theranostic Nanomedicines for NIR-II Fluorescence Imaging-Guided and Targeted NIR-II Photothermal Therapy of Subcutaneous Glioblastoma,” Colloids and Surfaces. B, Biointerfaces 245, no. 1 (2025): 114258.

[322] M. Kodali, O. W. Castro, D.-K. Kim, et al., “Intranasally Administered Human MSC-Derived Extracellular Vesicles Pervasively Incorporate Into Neurons and Microglia in Both Intact and Status Epilepticus Injured Forebrain,” International Journal of Molecular Sciences 21, no. 1 (2020): 181.

[323] S. Herman, I. Fishel, and D. Offen, “Intranasal Delivery of Mesenchymal Stem Cells-Derived Extracellular Vesicles for the Treatment of Neurological Diseases,” Stem Cells 39, no. 12 (2021): 1589-1600.

[324] M. J. Haney, N. L. Klyachko, Y. Zhao, et al., “Exosomes as Drug Delivery Vehicles for Parkinson's Disease Therapy (vol 207, pg 18, 2015),” Journal of Controlled Release 339, no. 1 (2021): 232-234.

[325] X. Zhuang, X. Xiang, W. Grizzle, et al., “Corrigendum: Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-Inflammatory Drugs From the Nasal Region to the Brain,” Molecular Therapy 2012; 20(1): 239-239.

[326] C. C. Chen, L. Liu, F. Ma, et al., “Elucidation of Exosome Migration Across the Blood-Brain Barrier Model in Vitro,” Cellular and Molecular Bioengineering 9, no. 4 (2016): 509-529.

[327] Y. Qi, L. Guo, Y. Jiang, et al., “Brain Delivery of Quercetin-Loaded Exosomes Improved Cognitive Function in AD Mice by Inhibiting Phosphorylated Tau-Mediated Neurofibrillary Tangles,” Drug Delivery 27, no. 1 (2020): 745-755.

[328] M. Sheykhhasan, R. Amini, S. S. Asl, et al., “Neuroprotective Effects of Coenzyme Q10-Loaded Exosomes Obtained From Adipose-Derived Stem Cells in a Rat Model of Alzheimer's Disease,” Biomedicine & Pharmacotherapy 152, no. 5 (2022): 113224.

[329] T. Katsuda, R. Tsuchiya, N. Kosaka, et al., “Human Adipose Tissue-Derived Mesenchymal Stem Cells Secrete Functional Neprilysin-Bound Exosomes,” Scientific Reports 3, no. 8 (2013): 1197.

[330] N. E.-M. B. Ahmed, M. Murakami, Y. Hirose, and M. Nakashima, “Therapeutic Potential of Dental Pulp Stem Cell Secretome for Alzheimer's Disease Treatment: An in Vitro Study,” Stem Cells International 2016, no. 5 (2016): 8102478.

[331] S. Liu, M. Fan, J.-X. Xu, et al., “Exosomes Derived From Bone-Marrow Mesenchymal Stem Cells Alleviate Cognitive Decline in AD-Like Mice by Improving BDNF-Related Neuropathology,” Journal of Neuroinflammation 19, no. 1 (2022): 35.

[332] Y.-A. Chen, C.-H. Lu, C.-C. Ke, et al., “Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer's Disease Pathology and Improve Cognitive Deficits,” Biomedicines 9, no. 6 (2021): 594.

[333] L. Yang, Y. Zhai, Y. Hao, Z. Zhu, and G. Cheng, “The Regulatory Functionality of Exosomes Derived From hUMSCs in 3D Culture for Alzheimer's Disease Therapy,” Small 16, no. 3 (2020): 1906273.

[334] G.-H. Cui, H.-D. Guo, and H. Li, “RVG-Modified Exosomes Derived From Mesenchymal Stem Cells Rescue Memory Deficits by Regulating Inflammatory Responses in a Mouse Model of Alzheimer's Disease,” Immunity & Ageing 16, no. 9 (2019): 10.

[335] C. Yang, Y. Song, M. Luo, et al., “Exosomes-Encapsulated Biomimetic Polydopamine Carbon Dots With Dual-Targeting Effect Alleviate Motor and Non-Motor Symptoms of Parkinson's Disease via Anti-Neuroinflammation,” International Journal of Biological Macromolecules 296, no. 2 (2025): 139724.

[336] S. Luo, X. Sun, M. Huang, et al., “Enhanced Neuroprotective Effects of Epicatechin Gallate Encapsulated by Bovine Milk-Derived Exosomes Against Parkinson's Disease Through Antiapoptosis and Antimitophagy,” Journal of Agricultural and Food Chemistry 69, no. 17 (2021): 5134-5143.

[337] L. Liu, Y. Li, H. Peng, et al., “Targeted Exosome Coating Gene-Chem Nanocomplex as “Nanoscavenger” for Clearing α-Synuclein and Immune Activation of Parkinson's Disease,” Science Advances 6, no. 50 (2020): 3967.

[338] J. M. Cooper, P. B. O. Wiklander, J. Z. Nordin, et al., “Systemic Exosomal siRNA Delivery Reduced Alpha-Synuclein Aggregates in Brains of Transgenic Mice,” Movement Disorders 29, no. 12 (2014): 1476-1485.

[339] M. Izco, J. Blesa, M. Schleef, et al., “Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology,” Molecular Therapy 27, no. 12 (2019): 2111-2122.

[340] X. Ren, Y. Zhao, F. Xue, et al., “Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model,” Molecular Therapy Nucleic Acids 17, no. 1 (2019): 726-740.

[341] Q. Li, Z. Wang, H. Xing, Y. Wang, and Y. Guo, “Exosomes Derived From miR-188-3p-Modified Adipose-Derived Mesenchymal Stem Cells Protect Parkinson's Disease,” Molecular Therapy Nucleic Acids 23, no. 7 (2021): 1334-1344.

[342] H. Peng, Y. Li, and W. Ji, “Intranasal Administration of Self-Oriented Nanocarriers Based on Therapeutic Exosomes for Synergistic Treatment of Parkinson's Disease,” ACS Nano 16, no. 1 (2022): 869-884.

[343] Y. Geng, X. Long, Y. Zhang, et al., “FTO-Targeted siRNA Delivery by MSC-Derived Exosomes Synergistically Alleviates Dopaminergic Neuronal Death in Parkinson's Disease via m6A-Dependent Regulation of ATM mRNA,” Journal of Translational Medicine 21, no. 1 (2023): 652.

[344] W. Kong, X. Li, X. Guo, et al., “Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of α-Synuclein Gene in a Mouse Model of Parkinson's Disease,” ACS Nano 18, no. 11 (2024): 7837-7851.

[345] S.-T. Lee, W. Im, J.-J. Ban, et al., “Exosome-Based Delivery of miR-124 in a Huntington's Disease Model,” Journal of Movement Disorders 10, no. 1 (2017): 45-52.

[346] T. Gschwendtberger, N. Thau-Habermann, J. von der Ohe, et al., “Protective Effects of EVs/Exosomes Derived From Permanently Growing Human MSC on Primary Murine ALS Motor Neurons,” Neuroscience Letters 816, no. 1 (2023): 137493.

[347] M. Lee, J.-J. Ban, K. Y. Kim, et al., “Adipose-Derived Stem Cell Exosomes Alleviate Pathology of Amyotrophic Lateral Sclerosis in Vitro,” Biochemical and Biophysical Research Communications 479, no. 3 (2016): 434-439.

[348] R. Bonafede, E. Turano, I. Scambi, et al., “ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS,” International Journal of Molecular Sciences 21, no. 10 (2020): 3651.

[349] E. Calabria, I. Scambi, R. Bonafede, et al., “ASCs-Exosomes Recover Coupling Efficiency and Mitochondrial Membrane Potential in an in Vitro Model of ALS,” Frontiers in Neuroscience 13, no. 4 (2019): 1070.

[350] X.-Y. Wu, B.-Y. Liao, and D. Xiao, “Encapsulation of Bryostatin-1 by Targeted Exosomes Enhances Remyelination and Neuroprotection Effects in the Cuprizone-Induced Demyelinating Animal Model of Multiple Sclerosis,” Biomaterials Science 10, no. 3 (2022): 714-727.

[351] X. Zheng, K. Sun, Y. Liu, et al., “Resveratrol-Loaded Macrophage Exosomes Alleviate Multiple Sclerosis Through Targeting Microglia,” Journal of Controlled Release 353, no. 1 (2023): 675-684.

[352] Z. Li, F. Liu, X. He, et al., “Exosomes Derived From Mesenchymal Stem Cells Attenuate Inflammation and Demyelination of the Central Nervous System in EAE Rats by Regulating the Polarization of Microglia,” International Immunopharmacology 67, no. 8 (2019): 268-280.

[353] A. Tamaoka, “Current Clinical Trials in the Treatment of Alzheimer's Disease,” Brain Nerve 72, no. 1 (2020): 23-34.

[354] J. Cummings, “New Approaches to Symptomatic Treatments for Alzheimer's Disease,” Molecular Neurodegeneration 16, no. 1 (2021): 2.

[355] K. Kumar, A. Kumar, R. M. Keegan, and R. Deshmukh, “Recent Advances in the Neurobiology and Neuropharmacology of Alzheimer's Disease,” Biomedicine & Pharmacotherapy 98, no. 6 (2018): 297-307.

[356] M. Fernandes, I. Lopes, L. Magalhaes, et al., “Novel Concept of Exosome-Like Liposomes for the Treatment of Alzheimer's Disease,” Journal of Controlled Release 336, no. 1 (2021): 130-143.

[357] A. Bulloj, M. C. Leal, H. Xu, E. M. Castano, and L. Morelli, “Insulin-Degrading Enzyme Sorting in Exosomes: A Secretory Pathway for a Key Brain Amyloid-β Degrading Protease,” Journal of Alzheimer's Disease 19, no. 1 (2010): 79-95.

[358] M.-A. Micci, B. Krishnan, E. Bishop, et al., “Hippocampal Stem Cells Promotes Synaptic Resistance to the Dysfunctional Impact of Amyloid Beta Oligomers via Secreted Exosomes,” Molecular Neurodegeneration 14, no. 1 (2019): 25.

[359] L. Zhai, H. Shen, Y. Sheng, and Q. Guan, “ADMSC Exo-MicroRNA-22 Improve Neurological Function and Neuroinflammation in Mice With Alzheimer's Disease,” Journal of Cellular and Molecular Medicine 25, no. 15 (2021): 7513-7523.

[360] C. P. Lai, O. Mardini, M. Ericsson, et al., “Dynamic Biodistribution of Extracellular Vesicles in Vivo Using a Multimodal Imaging Reporter,” ACS Nano 8, no. 1 (2014): 483-494.

[361] C. Singer and S. G. Reich, “Parkinson Disease Preface,” Clinics in Geriatric Medicine 36, no. 1 (2020): XIII-XIV.

[362] B. Kumar, M. Pandey, F. H. Pottoo, et al., “Liposomes: Novel Drug Delivery Approach for Targeting Parkinson's Disease,” Current Pharmaceutical Design 26, no. 37 (2020): 4721-4737.

[363] M. J. Haney, N. L. Klyachko, Y. Zhao, et al., “Exosomes as Drug Delivery Vehicles for Parkinson's Disease Therapy,” Journal of Controlled Release 207, no. 8 (2015): 18-30.

[364] C. Han, N. Xiong, X. Guo, et al., “Exosomes From Patients With Parkinson's Disease Are Pathological in Mice,” Journal of Molecular Medicine (Berl) 97, no. 9 (2019): 1329-1344.

[365] R. Kojima, D. Bojar, G. Rizzi, et al., “Designer Exosomes Produced by Implanted Cells Intracerebrally Deliver Therapeutic Cargo for Parkinson's Disease Treatment,” Nature Communications 9, no. 5 (2018): 1305.

[366] W. Meng, C. He, Y. Hao, et al., “Prospects and Challenges of Extracellular Vesicle-Based Drug Delivery System: Considering Cell Source,” Drug Delivery 27, no. 1 (2020): 585-598.

[367] N. Sharma and B. Nehru, “Curcumin Affords Neuroprotection and Inhibits α-Synuclein Aggregation in Lipopolysaccharide-Induced Parkinson's Disease Model,” Inflammopharmacology 26, no. 2 (2018): 349-360.

[368] C. R. Fields, N. Bengoa-Vergniory, and R. Wade-Martins, “Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease,” Frontiers in Molecular Neuroscience 12, no. 11 (2019): 299.

[369] Y. Yang, S. Okada, and M. Sakurai, “Adenosine-to-Inosine RNA Editing in Neurological Development and Disease,” RNA Biology 18, no. 7 (2021): 999-1013.

[370] X. Meng, J. Zhong, C. Zeng, et al., “MiR-30a-5p Regulates GLT-1 Function via a PKCα-Mediated Ubiquitin Degradation Pathway in a Mouse Model of Parkinson's Disease,” ACS Chemical Neuroscience 12, no. 9 (2021): 1578-1592.

[371] Y. Jiang, J. Liu, L. Chen, et al., “Serum Secreted miR-137-Containing Exosomes Affects Oxidative Stress of Neurons by Regulating OXR1 in Parkinson's Disease,” Brain Research 1722, no. 1 (2019): 146331.

[372] W. Huang, T. Zhang, X. Li, et al., “Intranasal Administration of Umbilical Cord Mesenchymal Stem Cell Exosomes Alleviates Parkinson's Disease,” Neuroscience 549, no. 1 (2024): 1-12.

[373] S. Byun, M. Lee, and M. Kim, “Gene Therapy for Huntington's Disease: The Final Strategy for a Cure?,” Journal of Movement Disorders 15, no. 1 (2022): 15-20.

[374] P. Pereira, J. A. Queiroz, A. Figueiras, and F. Sousa, “Current Progress on microRNAs-Based Therapeutics in Neurodegenerative Diseases,” Wiley Interdisciplinary Reviews: RNA 8, no. 3 (2017): 1409.

[375] Y. Sun, Z.-M. Luo, X.-M. Guo, D.-F. Su, and X. Liu, “An Updated Role of microRNA-124 in Central Nervous System Disorders: A Review,” Frontiers in Cellular Neuroscience 9, no. 2 (2015): 193.

[376] B. Ridolfi and H. Abdel-Haq, “Neurodegenerative Disorders Treatment: The MicroRNA Role,” Current Gene Therapy 17, no. 5 (2017): 327-363.

[377] T. Liu, W. Im, I. Mook-Jung, and M. Kim, “MicroRNA-124 Slows Down the Progression of Huntington's Disease by Promoting Neurogenesis in the Striatum,” Neural Regeneration Research 10, no. 5 (2015): 786-791.

[378] J. F. Alterman, L. M. Hall, A. H. Coles, et al., “Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain,” Molecular Therapy Nucleic Acids 4, no. 8 (2015): e266.

[379] M.-C. Didiot, L. M. Hall, A. H. Coles, et al., “Exosome-Mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing,” Molecular Therapy 24, no. 10 (2016): 1836-1847.

[380] T. Wu, M. Yu, L. Zhang, X. Chen, and Z. Pei, “Systemic Injection of Exosomal SIRNA Significantly Reduced Huntingtin Expression in Transgenic Mice of Huntington's Disease,” Journal of Neurology, Neurosurgery, and Psychiatry 89, no. 6 (2018): A88-A89.

[381] A. Biscans, R. A. Haraszti, D. Echeverria, et al., “Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles,” Molecular Therapy 26, no. 6 (2018): 1520-1528.

[382] S. Isfort, M. Crysandt, D. Gezer, et al., “Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor,” Recent Results in Cancer Research 212, no. 5 (2018): 87-108.

[383] S. Kubo, S. Nakayamada, and Y. Tanaka, “Baricitinib for the Treatment of Rheumatoid Arthritis,” Expert Review of Clinical Immunology 12, no. 9 (2016): 911-919.

[384] A. Ketabforoush, R. Chegini, S. Barati, et al., “Masitinib: The Promising Actor in the Next Season of the Amyotrophic Lateral Sclerosis Treatment Series,” Biomedicine & Pharmacotherapy 160, no. 12 (2023): 114378.

[385] J. Mandrioli, R. D'Amico, and E. Zucchi, “Randomized, Double-Blind, Placebo-Controlled Trial of Rapamycin in Amyotrophic Lateral Sclerosis,” Nature Communications 14, no. 1 (2023): 4970.

[386] R. L. Potenza, M. Armida, and P. Popoli, “Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review,” International Journal of Molecular Sciences 25, no. 3 (2024): 1751.

[387] K. Wang, Y. Li, C. Ren, et al., “Extracellular Vesicles as Innovative Treatment Strategy for Amyotrophic Lateral Sclerosis,” Frontiers in Cell and Developmental Biology 9, no. 1 (2021): 754630.

[388] P. J. Goldschmidt-Clermont, A. Khan, G. Jimsheleishvili, et al., “Treating Amyotrophic Lateral Sclerosis With Allogeneic Schwann Cell-Derived Exosomal Vesicles: A Case Report,” Neural Regeneration Research 20, no. 4 (2025): 1207-1216.

[389] L. Mazzini, F. De Marchi, L. Buzanska, et al., “Current Status and New Avenues of Stem Cell-Based Preclinical and Therapeutic Approaches in Amyotrophic Lateral Sclerosis,” Expert Opinion on Biological Therapy 24, no. 9 (2024): 933-954.

[390] A. I. Qureshi, G. Bartlett-Esquilant, A. Brown, et al., “Pragmatic Clinical Trials in Neurology,” Annals of Neurology 97, no. 6 (2025): 1022-1037.

[391] H. Wiendl, K. V. Toyka, P. Rieckmann, et al., “Basic and Escalating Immunomodulatory Treatments in Multiple Sclerosis: Current Therapeutic Recommendations,” Journal of Neurology 255, no. 10 (2008): 1449-1463.

[392] D. E. Harlow, J. M. Honce, and A. A. Miravalle, “Remyelination Therapy in Multiple Sclerosis,” Frontiers in Neurology 6, no. 10 (2015): 257.

[393] D. Denise Ojeda-Hernandez, M. A. Hernandez-Sapiens, E. E. Reza-Zaldivar, et al., “Exosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis,” Life (Basel) 12, no. 9 (2022): 1417.

[394] F. Chu, M. Shi, C. Zheng, et al., “The Roles of Macrophages and Microglia in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis,” Journal of Neuroimmunology 318, no. 9 (2018): 1-7.

[395] L. Yu, F. Yang, L. Jiang, et al., “Exosomes With Membrane-Associated TGF-β1 From Gene-Modified Dendritic Cells Inhibit Murine EAE Independently of MHC Restriction,” European Journal of Immunology 43, no. 9 (2013): 2461-2472.

[396] S. Haase and R. A. Linker, “Inflammation in Multiple Sclerosis,” Therapeutic Advances in Neurological Disorders 14, no. 8 (2021): 17562864211007687.

[397] M. Riazifar, M. R. Mohammadi, E. J. Pone, et al., “Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders,” ACS Nano 13, no. 6 (2019): 6670-6688.

[398] X. Zhuang, X. Xiang, W. Grizzle, et al., “Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-Inflammatory Drugs From the Nasal Region to the Brain,” Molecular Therapy 19, no. 10 (2011): 1769-1779.

[399] S. M. Mousavi, S. Hosseindoost, S. M. A. Mahdian, et al., “Exosomes Released From U87 Glioma Cells Treated With Curcumin and/or Temozolomide Produce Apoptosis in Naive U87 Cells,” Pathology, Research and Practice 245, no. 1 (2023): 154427.

[400] H. Liu, D. Cui, S. Huangfu, et al., “VCAM-1 Mesenchymal Stem/Stromal Cells Reveal Preferable Efficacy Upon an Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis Over the VCAM-1- Counterpart,” Neurochemical Research 50, no. 1 (2025): 40.

[401] K. Clark, S. Zhang, S. Barthe, et al., “Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Myelin Regeneration in an Animal Model of Multiple Sclerosis,” Cells 8, no. 12 (2019): 1497.

[402] Q. Zhang, L. Fu, Y. Liang, et al., “Exosomes Originating From MSCs Stimulated With TGF- and IFN- Promote Treg Differentiation,” Journal of Cellular Physiology 233, no. 9 (2018): 6832-6840.

[403] F. Laso-Garcia, J. Ramos-Cejudo, and F. Javier Carrillo-Salinas, “Therapeutic Potential of Extracellular Vesicles Derived From Human Mesenchymal Stem Cells in a Model of Progressive Multiple Sclerosis,” PLoS ONE 13, no. 9 (2018): e201797.

[404] J. Zhang, B. A. Buller, Z. G. Zhang, et al., “Exosomes Derived From Bone Marrow Mesenchymal Stromal Cells Promote Remyelination and Reduce Neuroinflammation in the Demyelinating Central Nervous System,” Experimental Neurology 347, no. 1 (2022): 113895.

[405] A. Fallah, A. A. Imani Fooladi, S. A. Havaei, M. Mahboobi, and H. Sedighian, “Recent Advances in Aptamer Discovery, Modification and Improving Performance,” Biochemistry and Biophysics Reports 40, no. 1 (2024): 101852-101852.

[406] M. Fereidan-Esfahani, W. Y. Yue, B. Wilbanks, et al., “Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes in Vitro,” Pharmaceuticals 13, no. 11 (2020): 403.

[407] F. H. Shamili, M. Alibolandi, H. Rafatpanah, et al., “Immunomodulatory Properties of MSC-Derived Exosomes Armed With High Affinity Aptamer Toward Mylein as a Platform for Reducing Multiple Sclerosis Clinical Score,” Journal of Controlled Release 299, no. 4 (2019): 149-164.

[408] Q. Wang, S. Cheng, F. Qin, A. Fu, and C. Fu, “Application Progress of RVG Peptides to Facilitate the Delivery of Therapeutic Agents Into the Central Nervous System,” RSC Advances 11, no. 15 (2021): 8505-8515.

[409] Y. Zhai, Q. Wang, Z. Zhu, et al., “High-Efficiency Brain-Targeted Intranasal Delivery of BDNF Mediated by Engineered Exosomes to Promote Remyelination,” Biomaterials Science 10, no. 19 (2022): 5707-5718.

[410] G. E. Melling, E. Carollo, R. Conlon, J. C. Simpson, and D. R. F. Carter, “The Challenges and Possibilities of Extracellular Vesicles as Therapeutic Vehicles,” European Journal of Pharmaceutics and Biopharmaceutics 144, no. 6 (2019): 50-56.

[411] L. Li, G. Jiang, W. Yu, et al., “Preparation of Chitosan-Based Multifunctional Nanocarriers Overcoming Multiple Barriers for Oral Delivery of Insulin,” Materials Science & Engineering. C, Materials for Biological Applications 70, no. 10 (2017): 278-286.

[412] M. L. Merchant, I. M. Rood, J. K. J. Deegens, and J. B. Klein, “Isolation and Characterization of Urinary Extracellular Vesicles: Implications for Biomarker Discovery,” Nature Reviews Nephrology 13, no. 12 (2017): 731-749.

[413] C. F. Ruivo, B. Adem, M. Silva, and S. A. Melo, “The Biology of Cancer Exosomes: Insights and New Perspectives,” Cancer Research 77, no. 23 (2017): 6480-6488.

[414] J. Xie, Z. Shen, Y. Anraku, K. Kataoka, and X. Chen, “Nanomaterial-Based Blood-Brain-Barrier (BBB) Crossing Strategies,” Biomaterials 224, no. 5 (2019): 119491.

[415] C. Gardiner, D. Di Vizio, S. Sahoo, et al., “Techniques Used for the Isolation and Characterization of Extracellular Vesicles: Results of a Worldwide Survey,” Journal of Extracellular Vesicles 5, no. 6 (2016): 32945.

[416] L.-H. Huang, C.-S. Rau, S.-C. Wu, et al., “Identification and Characterization of hADSC-Derived Exosome Proteins From Different Isolation Methods,” Journal of Cellular and Molecular Medicine 25, no. 15 (2021): 7436-7450.

[417] P. Sharma, S. Ludwig, L. Muller, et al., “Immunoaffinity-Based Isolation of Melanoma Cell-Derived Exosomes From Plasma of Patients With Melanoma,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1435138.

[418] L. M. Doyle and M. Z. Wang, “Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis,” Cells 8, no. 7 (2019): 727.

[419] M. Pradhan, K. Yadav, D. Singh, and M. R. Singh, “Topical Delivery of Fluocinolone Acetonide Integrated NLCs and Salicylic Acid Enriched Gel: A Potential and Synergistic Approach in the Management of Psoriasis,” Journal of Drug Delivery Science and Technology 61, no. 4 (2021): 102282.

[420] E. V. Batrakova and M. S. Kim, “Development and Regulation of Exosome-Based Therapy Products,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 8, no. 5 (2016): 744-757.

[421] M. J. Haney, N. L. Klyachko, Y. Zhao, A. V. Kabanov, and E. V. Batrakova, “Extracellular Vesicles as Drug Delivery Vehicles for Potent Redox Enzyme Catalase to Treat Parkinson's Disease,” Free Radical Biology and Medicine 128, no. 5 (2018): S18-S18.

[422] D.-K. Kim, H. Nishida, and S. Y. An, “Chromatographically Isolated CD63+ CD81+Extracellular Vesicles From Mesenchymal Stromal Cells Rescue Cognitive Impairments After TBI,” Proceeding of the National Academy of Sciences of the United States of America 113, no. 1 (2016): 170-175.

[423] Y. Yamada, “Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes,” Cancers 13, no. 19 (2021): 5002.

[424] D. Ha, N. Yang, and V. Nadithe, “Exosomes as Therapeutic Drug Carriers and Delivery Vehicles Across Biological Membranes: Current Perspectives and Future Challenges,” Acta Pharmaceutica Sinica B 6, no. 4 (2016): 287-296.

[425] F. Sonvico, A. Clementino, F. Buttini, et al., “Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting,” Pharmaceutics 10, no. 1 (2018): 34.

[426] A. Salvati, A. S. Pitek, M. P. Monopoli, et al., “Transferrin-Functionalized Nanoparticles Lose Their Targeting Capabilities When a Biomolecule Corona Adsorbs on the Surface,” Nature Nanotechnology 8, no. 2 (2013): 137-143.

[427] L.-Y. Chen, T.-W. Kao, C.-C. Chen, et al., “Frontier Review of the Molecular Mechanisms and Current Approaches of Stem Cell-Derived Exosomes,” Cells 12, no. 7 (2023): 1018.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.